Methods and compositions for sustained immunotherapy

ABSTRACT

This disclosure provides methods of making functionalized PEG iron oxide nanoparticles.

CROSS-REFERENCE TO RELATED APPLICATION

This application is a Divisional Application of U.S. application Ser.No. 16/132,000, filed Sep. 14, 2018, which is a Divisional Applicationof U.S. application Ser. No. 14/531,707, filed Nov. 3, 2014, whichclaims priority under 35 U.S.C. § 119(e) to U.S. Provisional PatentApplication No. 61/899,826, filed Nov. 4, 2013, the entire contents ofeach are hereby incorporated by reference into the present disclosure.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has beensubmitted electronically in ASCII format and is hereby incorporated byreference in its entirety. Said ASCII copy, created on Dec. 5, 2014, isnamed 378701-0651_SL.txt and is 11,629 bytes in size.

FIELD OF DISCLOSURE

This disclosure is directed to compositions and methods related toimmunotherapy and medicine.

BACKGROUND

Throughout and within this disclosure are technical and patentpublications, referenced by an identifying citation or by an Arabicnumber. The full bibliographic citation corresponding to the Arabicnumber is found in the specification, preceding the claims. Thedisclosures of all references cited herein are incorporated by referenceinto the present application to more fully describe the state of the artto which this invention pertains.

Autoimmune diseases are caused by an attack of self-tissues by theimmune system. An ideal therapy would be one capable of selectivelyblunting the autoimmune response (against all antigenic epitopestargeted in that disease) without impairing systemic immunity (immuneresponses to foreign antigens). Unfortunately, the lymphocytespecificities involved in any one autoimmune disease are many andincompletely defined, making this a challenging goal.

SUMMARY

In response to this need in the art, described herein are therapeuticcompositions useful in treating autoimmune disorders. One aspect relatesto a method for expanding and/or developing populations ofanti-pathogenic autoreactive T cells and/or B-cells in a subject in needthereof, which method comprises, or consists essentially of, or yetfurther consists of, administering to that subject an antigen-MHC classII-nanoparticle (“NP”) complex (“NP-complex”), wherein the antigen is anautoimmunity related antigen or autoantigen. In some aspects all theantigens on the particular NP are identical or they can be different. Inanother aspect, the antigens on the NP have different amino acidsequences but are isolated from the same antigenic protein. In a furtheraspect, the antigens on the NP are from different antigens. In anotheraspect, the MHCII are the same or different.

In one aspect, this disclosure provides a NP-complex comprising, oralternatively consisting essentially of, or yet further consisting of, ananoparticle; a MHC class II protein and a disease-relevant antigen thatcan be in the form of an antigen/MHCII complex, for use in expandingand/or developing one or more populations of B-regulatory cells and TR1cells (e.g., TR1 and CD4+ cells), in a subject, wherein the nanoparticlehas a diameter selected from the group of: from about 1 nm to about 100nm in diameter; from about 1 nm to about 50 nm in diameter or from about1 nm to about 20 nm or from about 5 nm to about 20 nm in diameter andthe ratio of the number of antigen-MHCII complexes to nanoparticles isfrom about 10:1 to about 1000:1. In one aspect, the complex has a MHCclass II density from about 0.05 pMHCII/100 nm² NP surface area(including coating) to about 25 pMHCII/100 nm² NP surface area(including coating). The antigen is an autoantigen involved in anautoimmune response or mimic thereof such as, for example, pre-diabetes,diabetes, multiple sclerosis (“MS”) or a multiple sclerosis-relateddisorder, and optionally wherein when the disease is pre-diabetes ordiabetes, the autoantigen is an epitope from an antigen expressed bypancreatic beta cells or the autoantigen IGRP, Insulin, GAD or IA-2protein. In another aspect, the MHC class II component comprises all orpart of a HLA-DR, HLA-DQ, or HLA-DP. The antigen-MHC class II complex iscovalently or non-covalently linked to the nanoparticle. Thenanoparticle can be bioabsorbable and/or biodegradable.

In a further aspect, the nanoparticle is non-liposomal and/or has asolid core, preferably a gold or iron oxide core. When covalentlylinked, the antigen-MHC class II complex is covalently linked to thenanoparticle through a linker less than 5 kD in size. In one aspect, thelinker comprises polyethylene glycol (PEG). The pMHC can be linked tothe nanoparticle or the nanoparticle coating by any structure, includingbut not limited to linkers or by cross-linking. In one aspect, the MHCis linked to the nanoparticle or the coating directionally through theC-terminus.

Applicant has discovered that the density of the antigen-MHC class IIcomplexes on the nanoparticle contributes to the therapeutic benefit.Thus as disclosed herein, the antigen-MHCII nanoparticle complex canhave a defined density in the range of from about 0.05 MHC molecules per100 nm² of surface area of the nanoparticle (the surface area measuredto include any coating), assuming at least 2 MHCII, or alternatively atleast 8, or alternatively at least 9, or alternatively at least 10, oralternatively at least 11, or alternatively at least 12, MHCII complexedto the nanoparticle. In one aspect the complex has a density of MHCIIfrom about 0.01 MHCII per 100 nm² (0.05 MHCII/100 nm²) to about 30MHCII/100 nm², or alternatively from 0.1 MHCII/100 nm² to about 25MHCII/100 nm², or alternatively from about 0.3 MHCII/100 nm² to about 25MHCII/100 nm², or alternatively from about 0.4 MHCII/100 nm² to about 25MHCII/100 nm², or alternatively from about 0.5 MHCII/100 nm² to about 20MHCII/100 nm², or alternatively from 0.6 MHCII/100 nm² to about 20MHCII/100 nm², or alternatively from about 1.0 MHCII/100 nm² to about 20MHCII/100 nm², or alternatively from about 5.0 MHCII/100 nm² to about 20MHCII/100 nm², or alternatively from about 10.0 MHCII/100 nm² to about20 MHCII/100 nm², or alternatively from about 15 MHCII/100 nm² to about20 MHCII/100 nm², or alternatively at least about 0.5, or alternativelyat least about 1.0, or alternatively at least about 5.0, oralternatively at least about 10.0, or alternatively at least about 15.0MHCII/100 nm², the nm² surface area of the nanoparticle to include anycoating. In one aspect, when 9 or at least 9 MHCII are complexed to ananoparticle, the density range is from about 0.3 MHCII/100 nm² to about20 MHCII/100 nm².

This disclosure also provides a composition comprising a therapeuticallyeffective amount of the NP-complex as described herein and a carrier,e.g., a pharmaceutically acceptable carrier. In one aspect, allNP-complexes in the composition are identical. In another aspect, theNP-complexes of the composition include diverse or different MHC-antigencomplexes.

Methods to make the complexes and compositions are further providedherein. The method can comprise, or alternatively consist essentiallyof, or yet further consist of, non-covalently coating or covalentlycomplexing antigen-MHC complexes (e.g., MHCII complexes) onto ananoparticle.

Medical and diagnostic methods are also provided. In one aspect, amethod is provided for promoting the formation, expansion andrecruitment of B-regulatory cells and/or TR1 cells (e.g., TR1 and CD4+cells) in an antigen-specific manner in a subject in need thereof,comprising, or alternatively consisting essentially of, or yet furtherconsisting of, administering to the subject an effective amount of theNP-complex or composition as described herein.

In another aspect, a method for treating or preventing an autoimmunedisease or disorder as described herein, e.g., MS, a MS-relateddisorder, diabetes or pre-diabetes, in a subject in need thereof isprovided, the method comprising, or alternatively consisting essentiallyof, or yet further consisting of, administering to the subject aneffective amount of the NP-complex or composition as described herein,wherein the autoantigen is disease-relevant for the disease to betreated, e.g., for the prevention or treatment of diabetes, the antigenis a diabetes-relevant antigen. In a further aspect, the autoimmunedisease is MS or a MS-related disorder and the antigen is MS-relevant.

Kits are also provided. The kits comprise, or alternatively consistessentially of, or yet further consist of a NP-complex as describedherein or a composition and instructions for use.

In one aspect, provided herein is a method of making nanoparticlescomprising thermally decomposing or heating a nanoparticle precursor. Inone embodiment, the nanoparticle is a metal or a metal oxidenanoparticle. In one embodiment, the nanoparticle is an iron oxidenanoparticle. In one embodiment, the nanoparticle is a goldnanoparticle. In one embodiment, provided herein are the nanoparticlesprepared in accordance with the present technology. In one embodiment,provided herein is a method of making iron oxide nanoparticlescomprising a thermal decomposition reaction of iron acetyl acetonate. Inone embodiment, the iron oxide nanoparticle obtained is water-soluble.In one aspect, iron oxide nanoparticle is suitable for proteinconjugation. In one embodiment, the method comprises a single-stepthermal decomposition reaction.

In one aspect, the thermal decomposition occurs in the presence offunctionalized PEG molecules. Certain non-limiting examples offunctionalized PEG linkers are shown in Table 1.

In one aspect, the thermal decomposition comprises heating iron acetylacetonate. In one embodiment, the thermal decomposition comprisesheating iron acetyl acetonate in the presence of functionalized PEGmolecules. In one embodiment, the thermal decomposition comprisesheating iron acetyl acetonate in the presence of benzyl ether andfunctionalized PEG molecules.

Without being bound by theory, in one embodiment, functionalized PEGmolecules are used as reducing reagents and as surfactants. The methodof making nanoparticles provided herein simplifies and improvesconventional methods, which use surfactants that are difficult to bedisplaced, or are not displaced to completion, by PEG molecules torender the particles water-soluble. Conventionally, surfactants can beexpensive (e.g., phospholipids) or toxic (e.g., Oleic acid oroleilamine). In another aspect, without being bound by theory, themethod of making nanoparticles obviates the need to use conventionalsurfactants, thereby achieving a high degree of molecular purity andwater solubility.

In one embodiment, the thermal decomposition involves iron acetylacetonate and benzyl ether and in the absence of conventionalsurfactants other than those employed herein.

In one embodiment, the temperature for the thermal decomposition isabout 80 to about 300° C., or about 80 to about 200° C., or about 80 toabout 150° C., or about 100 to about 250° C., or about 100 to about 200°C., or about 150 to about 250° C., or about 150 to about 250° C. In oneembodiment, the thermal decomposition occurs at about 1 to about 2 hoursof time.

In one embodiment, the method of making the iron oxide nanoparticlescomprises a purification step, such as by using Miltenyi Biotec LSmagnet column.

In one embodiment, the nanoparticles are stable at about 4° C. inphosphate buffered saline (PBS) without any detectable degradation oraggregation. In one embodiment, the nanoparticles are stable for atleast 6 months.

In one aspect, provided herein is a method of making nanoparticlecomplexes comprising contacting pMHC with iron oxide nanoparticlesprovided herein. Without being bound by theory, pMHC encodes a Cysteineat its carboxyterminal end, which can react with the maleimide group infunctionalized PEG at about pH 6.2 to about pH 6.5 for about 12 to about14 hours.

In one aspect, the method of making nanoparticle complexes comprises apurification step, such as by using Miltenyi Biotec LS magnet column.

DESCRIPTION OF THE DRAWINGS

The following drawings form part of the present specification and areincluded to further demonstrate certain aspects of the presentinvention. The invention may be better understood by reference to one ormore of these drawings in combination with the detailed description ofspecific embodiments presented herein.

FIGS. 1A-1C show schematics of NP-complexes. FIG. 1A is a schematic of asingle-chain pMHC-class I expression construct (top) and arepresentative flow cytometric profile of the binding of thecorresponding pMHC tetramer (fluorochrome-labeled) to cognate CD8+T-cells. FIG. 1A discloses “6×His” as SEQ ID NO: 70. FIG. 1B is aschematic showing the linkers and two dimensional structure ofNP-complexes. As can be seen, one NP can contain the same antigencomplexed to the nanoparticle core through various chemical linkers.FIG. 1B discloses “6×His” as SEQ ID NO: 70. FIG. 1C showsmaleimide-functionalized NPs conjugated to NPs.

FIG. 2 shows the structure of a typical pMHC class II monomer (top) anda representative FACS profile of cognate CD4+ T-cells stained with thecorresponding pMHC tetramer or left unstained. FIG. 2 discloses “6×His”as SEQ ID NO: 70.

FIGS. 3A-3B show different T1D-relevant pMHC class II-NPs reversehyperglycemia in newly diabetic NOD mice. FIG. 3A shows individual mouseblood glucose curves. Mice were considered ‘cured’ when stablynormoglycemic for 4 wk, after which treatment was withdrawn. HEL₁₄₋₂₂, aforeign antigen, was used as control. FIG. 3B shows incidence of diseasereversal.

FIG. 4 shows intraperitoneal glucose-tolerance tests (IPTGTTs) andinsulin-production capacity in long-term cured mice. IDDM, diabeticuntreated mice; Cured, mice with normoglycemia at 50 wk of age (>30 wkafter treatment withdrawal); Control, age-matched non-diabetic untreatedmice (50 wk-old).

FIG. 5 shows that T1D-relevant pMHC class II-NPs expand cognateautoreactive CD4+ T-cells. Data correspond to mice treated with 2.5mi/I-Ag7-NPs. Bottom right, expansion is specific for the pMHC on theNPs, as mice treated with 2.5 mi/I-Ag7-NPs did not show increasedpercentages of two other autoreactive CD4+ T-cell specificities. PLN,pancreatic lymph nodes; MN, mesenteric lymph nodes; BM, bone marrow (areservoir of memory T-cells).

FIG. 6 shows that T1D-relevant pMHC class II-NPs expand cognateautoreactive CD4+ T-cells. Expansion is shown for spleen but similarpatterns are seen in the pancreative lymph nodes, blood and marrow.“Onset” correspond to pre-treatment values; “Cured” are mice renderednormoglycemic with pMHC-NP (analyzed at >30 wk of treatment withdrawal);“IDDM” are mice that relapsed upon treatment withdrawal (˜25%); “50wk-old” corresponds to age-matched untreated non-diabetic controls.

FIG. 7 shows that T1D-relevant pMHC class II-NPs expand cognatememory-like T-regulatory-1 (“Tr1 or TR1”) cells.

FIG. 8 shows that the autoreactive CD4+ T-cells expanded by pMHC classII-NP are IL-10 producers. IGRP₁₂₆₋₁₄₅/I-A^(g7) tetramer+ cells frommice treated with IGRP₁₂₆₋₁₄₅/I-A^(g7)-NPs or control NPs were sorted,challenged with cognate and non-cognate peptides and the sups assayedfor cytokine content with luminex technology.

FIG. 9 shows that pMHC class II-NPs reverse hyperglycemia in an IL-10and TGFb-dependent manner. FIG. 9 shows ability of IGRP₄₋₂₂/IA^(g7)-NPsto restore normoglycemia (top), expand cognate Tr1 cells (bottom left)and suppress autoantigen presentation in the PLNs (toIGRP₂₀₆₋₂₁₄-reactive CD8+ T-cells; bottom right) of mice treated withcytokine blocking antibodies (“Abs”). Anti-IL10 and anti-TGFβ Abspartially restore autoantigen presentation and inhibit the therapeuticeffect of pMHC-NPs, without impairing Tr1 cell expansion.

FIGS. 10A-10B show that pMHC class II-NP therapy does not compromisesystemic immunity. FIG. 10A shows that pMHC-NP-treated NOD mice canreadily clear an acute viral (vaccinia virus) infection (bottom, compareday 4 versus day 14 after infection) despite systemic expansion ofautoregulatory Tr1 CD4+ T-cells (top). FIG. 10B shows thatpMHC-NP-treated mice (10 doses) can mount antibody responses againstKLH-DNP upon immunization in CFA, as compared to untreated andunvaccinated mice.

FIG. 11 shows that pMHC class II-NP therapy reduces the severity ofestablished EAE in C57BL/6 mice. B6 mice were immunized with pMOG35-55in CFA and treated with pertussis toxin i.v. Mice were scored for signsof EAE using established criteria over a 15-point scale. Affected micewere treated with two weekly doses of 7.5-22.5 ug ofpMOG₃₈₋₄₉/IA^(b)-coated NPs, beginning 21 days after immunization.

FIGS. 12A-12C show structure and properties of pMHC class II-NPs. FIG.12A is a cartoon depicting the different chemistries that can be used tocovalently coat pMHCs onto functionalized, biocompatible iron oxide NPs.FIG. 12B is a transmission electron micrograph of pMHC-coated NPs. FIG.12C shows Dynamic Light Scattering profiles of pMHC-coated vs. uncoatedNPs.

FIGS. 13A-13C show expansion and differentiation of cognate B-cells intoBreg cells in pMHC class II-NP-treated mice. In FIG. 13A, 1:1 mixturesof PKH26-labeled/pulsed with 2.5 mi peptide B-cells (bottom) (ordendritic cells, top) plus CFSE-labeled/GPI peptide-pulsed B-cells(bottom) (or dendritic cells, top) were injected into 2.5mi/IAg7-NP-treated NOD mice. Seven days later, the hosts were analyzedfor presence of both subsets of B-cells (bottom) or dendritic cells(top). Left panels show representative results and Right histograms showa summary of the results obtained over several experiments. The dataindicate that 2.5 mi-peptide-pulsed B-cells (but not DCs) expand in 2.5mi/IAg7-NP-treated NOD mice. In B (left panel), Applicant compared theB-cell content in the pancreatic (PLN) and mesenteric (MLN) lymph nodesof NOD mice treated with 2.5 mi/IAg7-NPs versus NPs coated with control(diabetes-irrelevant) pMHC-NPs. Data show increased recruitment ofB-cells in the former. In B (right panel), Applicant compared therecruitment of B-cells to the PLNs as a function of Tr1 cellrecruitment. Data were obtained using several different pMHC-NPpreparations. Data show a statistically-significant correlation betweenrecruitment of pMHC-NP-expanded TR1 cells and B-cell recruitment to thePLNs. In FIG. 13B, Applicant transfered B-cells, pulsed with 2.5 mi orcontrol peptides, from IL10-eGFP knock-in NOD mice into severaldifferent donor mouse types (top labels). After 7 days, spleens wereanalyzed for conversion of the transfused B-cells into IL10-producing(eGFP+) B-cells expressing high levels of CD1d and CD5 (B-regulatorycells). Data show robust expansion and conversion of cognate (2.5mi-loaded) B-cells into B-reg cells only in 2.5 mi/IAg7-NP-treatedhosts.

FIG. 14 shows synthesis of surface functionalized iron oxidenanoparticle by thermal decomposition of iron acetylacetonate andbioconjugation.

DETAILED DESCRIPTION

It is to be understood that this invention is not limited to particularembodiments described, as such may, of course, vary. It is also to beunderstood that the terminology used herein is for the purpose ofdescribing particular embodiments only, and is not intended to belimiting, since the scope of the present invention will be limited onlyby the appended claims.

It must be noted that as used herein and in the appended claims, thesingular forms “a”, “an”, and “the” include plural referents unless thecontext clearly dictates otherwise. Thus, for example, reference to “anexcipient” includes a plurality of excipients.

I. Definitions

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this invention belongs. As used herein the followingterms have the following meanings.

As used herein, the term “comprising” or “comprises” is intended to meanthat the compositions and methods include the recited elements, but notexcluding others. “Consisting essentially of” when used to definecompositions and methods, shall mean excluding other elements of anyessential significance to the combination for the stated purpose. Thus,a composition consisting essentially of the elements as defined hereinwould not exclude other materials or steps that do not materially affectthe basic and novel characteristic(s) of the claimed invention, such ascompositions for treating or preventing multiple sclerosis. “Consistingof” shall mean excluding more than trace elements of other ingredientsand substantial method steps. Embodiments defined by each of thesetransition terms are within the scope of this invention.

An “auto-reactive T cell” is a T cell that recognizes an “auto-antigen”,which is a molecule produced and contained by the same individual thatcontains the T cell.

A “pathogenic T cell” is a T cell that is harmful to a subjectcontaining the T cell. Whereas, a non-pathogenic T cell is notsubstantially harmful to a subject, and an anti-pathogenic T cellsreduces, ameliorates, inhibits, or negates the harm of a pathogenic Tcell.

As used herein the terms regulatory B-cells or B-regulatory cells(“B-regs”) intend those cells that are responsible for theanti-inflammatory effect, that is characterized by the expression ofCD1d, CD5 and the secretion of IL-10. B-regs are also identified byexpression of Tim-1 and can be induced through Tim-1 ligation to promotetolerance. The ability of being B-regs was shown to be driven by manystimulatory factors such as toll-like receptors, CD40-ligand and others.However, full characterization of B-regs is ongoing. B-regs also expresshigh levels of CD25, CD86, and TGF-β. This subset of B cells is able tosuppress Th1 proliferation, thus contributing to the maintenance ofself-tolerance. The potentiation of B-reg function should become the aimof many immunomodulatory drugs, contributing to a better control ofautoimmune diseases. See for example: ncbi.nlm.nih.gov/pubmed/23707422,last accessed on Oct. 31, 2013.

T Regulatory 1 cells (Tr1) are a subset of CD4+ T cells that haveregulatory properties and are able to suppress antigen-specific immuneresponses in vitro and in vivo. These T-regulatory 1 (Tr1) cells aredefined by their unique profile of cytokine production and make highlevels of IL-10 and TGF-beta, but no IL-4 or IL-2. The IL-10 andTGF-beta produced by these cells mediate the inhibition of primary naiveT cells in vitro. There is also evidence that Tr1 cells exist in vivo,and the presence of high IL-10-producing CD4(+) T cells in patients withsevere combined immunodeficiency who have received allogeneic stem-celltransplants have been documented. Tr1 cells are involved in theregulation of peripheral tolerance and they could potentially be used asa cellular therapy to modulate immune responses in vivo. See forexample: ncbi.nlm.nih.gov/pubmed/10887343, last accessed on Oct. 31,2013.

Type-1 T regulatory (Tr1) cells are defined by their ability to producehigh levels of IL-10 and TGF-beta. Tr1 cells specific for a variety ofantigens arise in vivo, but may also differentiate from naive CD4+ Tcells in the presence of IL-10 in vitro. Tr1 cells have a lowproliferative capacity, which can be overcome by IL-15. Tr1 cellssuppress naive and memory T helper type 1 or 2 responses via productionof IL-10 and TGF-beta. Further characterization of Tr1 cells at themolecular level will define their mechanisms of action and clarify theirrelationship with other subsets of Tr cells. The use of Tr1 cells toidentify novel targets for the development of new therapeutic agents,and as a cellular therapy to modulate peripheral tolerance, can beforeseen. See for example, ncbi.nlm.nih.gov/pubmed/11722624, lastaccessed on Oct. 31, 2013.

The terms “inhibiting,” “reducing,” or “prevention,” or any variation ofthese terms, when used in the claims and/or the specification includesany measurable decrease or complete inhibition to achieve a desiredresult.

Throughout this application, the term “about” is used to indicate that avalue includes the standard deviation of error for the device or methodbeing employed to determine the value. The term “about” when used beforea numerical designation, e.g., temperature, time, amount, andconcentration, including range, indicates approximations which may varyby (+) or (—) 10%, 5%, or 1%.

By “biocompatible”, it is meant that the components of the deliverysystem will not cause tissue injury or injury to the human biologicalsystem. To impart biocompatibility, polymers and excipients that havehad history of safe use in humans or with GRAS (Generally Accepted AsSafe) status, will be used preferentially. By biocompatibility, it ismeant that the ingredients and excipients used in the composition willultimately be “bioabsorbed” or cleared by the body with no adverseeffects to the body. For a composition to be biocompatible, and beregarded as non-toxic, it must not cause toxicity to cells. Similarly,the term “bioabsorbable” refers to nanoparticles made from materialswhich undergo bioabsorption in vivo over a period of time such that longterm accumulation of the material in the patient is avoided. In apreferred embodiment, the biocompatible nanoparticle is bioabsorbed overa period of less than 2 years, preferably less than 1 year and even morepreferably less than 6 months. The rate of bioabsorption is related tothe size of the particle, the material used, and other factors wellrecognized by the skilled artisan. A mixture of bioabsorbable,biocompatible materials can be used to form the nanoparticles used inthis invention. In one embodiment, iron oxide and a biocompatible,bioabsorbable polymer can be combined. For example, iron oxide and PGLAcan be combined to form a nanoparticle.

An antigen-MHC-nanoparticle complex (“NP-complex”) refers topresentation of a peptide, carbohydrate, lipid, or other antigenicsegment, fragment, or epitope of an antigenic molecule or protein (i.e.,self peptide or autoantigen) on a surface, such as a biocompatiblebiodegradable nanosphere. “Antigen” as used herein refers to all, part,fragment, or segment of a molecule that can induce an immune response ina subject or an expansion of anti-pathogenic cells.

A “mimic” is an analog of a given ligand or peptide, wherein the analogis substantially similar to the ligand. “Substantially similar” meansthat the analog has a binding profile similar to the ligand except themimic has one or more functional groups or modifications thatcollectively accounts for less than about 50%, less than about 40%, lessthan about 30%, less than about 20%, less than about 10%, or less thanabout 5% of the molecular weight of the ligand.

The term “anti-pathogenic autoreactive T cell” refers to a T cell withanti-pathogenic properties (i.e., T cells that counteract an autoimmunedisease such as MS, a MS-related disease or disorder, or pre-diabetes).These T cells can include anti-inflammatory T cells, effector T cells,memory T cells, low-avidity T cells, T helper cells, autoregulatory Tcells, cytotoxic T cells, natural killer T cells, TR1 cells, CD4+ Tcells, CD8+ T cells and the like.

The term “anti-inflammatory T cell” refers to a T cell that promotes ananti-inflammatory response. The anti-inflammatory function of the T cellmay be accomplished through production and/or secretion ofanti-inflammatory proteins, cytokines, chemokines, and the like.Anti-inflammatory proteins are also intended to encompassanti-proliferative signals that suppress immune responses.Anti-inflammatory proteins include IL-4, IL-10, IL-13, IL-21, IL-23,IL-27, IFN-α, TGF-β, IL-1ra, G-CSF, and soluble receptors for TNF andIL-6. Accordingly, aspects of the disclosure relate to methods fortreating, in a patient, an autoimmune disorder, such as MS, a MS-relateddisorder, diabetes or pre-diabetes, the method comprising, consistingessentially of or yet further consisting of administering to thatpatient an antigen-MHCII-nanoparticle complex, wherein the antigen is adisease-relevant antigen.

The term “IL-10” or “Interleukin-10” refers to a cytokine encoded by theIL-10 gene. The IL-10 sequence is represented by the GenBank AccessionNo.: NM_000572.2 (mRNA) and NP_000563.1 (protein).

The term “TGF-β” or “Transforming growth factor beta” refers to aprotein that can have an anti-inflammatory effect. TGF-β is a secretedprotein that exists in at least three isoforms called TGF-β1, TGF-β2 andTGF-β3. It was also the original name for TGF-β1, which was the foundingmember of this family. The TGF-β family is part of a superfamily ofproteins known as the transforming growth factor beta superfamily, whichincludes inhibins, activin, anti-müllerian hormone, bone morphogeneticprotein, decapentaplegic and Vg-1.

A “an effective amount” is an amount sufficient to achieve the intendedpurpose, non-limiting examples of such include: initiation of the immuneresponse, modulation of the immune response, suppression of aninflammatory response and modulation of T cell activity or T cellpopulations. In one aspect, the effective amount is one that functionsto achieve a stated therapeutic purpose, e.g., a therapeuticallyeffective amount. As described herein in detail, the effective amount,or dosage, depends on the purpose and the composition, component and canbe determined according to the present disclosure.

The use of the word “a” or “an” when used in conjunction with the term“comprising” in the claims and/or the specification may mean “one,” butit is also consistent with the meaning of “one or more,” “at least one,”and “one or more than one.”

By “nanosphere,” “NP,” or “nanoparticle” herein is meant a smalldiscrete particle that is administered singularly or pluraly to asubject, cell specimen or tissue specimen as appropriate. In certainembodiments, the nanoparticles are substantially spherical in shape. Incertain embodiments, the nanoparticle is not a liposome or viralparticle. In further embodiments, the nanoparticle is solid or has asolid core. The term “substantially spherical,” as used herein, meansthat the shape of the particles does not deviate from a sphere by morethan about 10%. Various known antigen or peptide complexes of theinvention may be applied to the particles. The nanoparticles of thisinvention range in size from about 1 nm to about 1 μm and, preferably,from about 1 nm to about 100 nm or alternatively from about 1 nm toabout 50 nm, or alternatively from about 5 to 50 nm or alternativelyfrom about 5 nm to 100 nm, and in some aspects refers to the average ormedian diameter of a plurality of nanoparticles when a plurality ofnanoparticles are intended. Smaller nanosize particles can be obtained,for example, by the process of fractionation whereby the largerparticles are allowed to settle in an aqueous solution. The upperportion of the solution is then recovered by methods known to those ofskill in the art. This upper portion is enriched in smaller sizeparticles. The process can be repeated until a desired average size isgenerated.

The use of the term “or” in the claims is used to mean “and/or” unlessexplicitly indicated to refer to alternatives only or the alternativesare mutually exclusive, although the disclosure supports a definitionthat refers to only alternatives and “and/or.”

As used herein the phrase “immune response” or its equivalent“immunological response” refers to the development of a cell-mediatedresponse (mediated by antigen-specific T cells or their secretionproducts). A cellular immune response is elicited by the presentation ofpolypeptide epitopes in association with Class I or Class II MHCmolecules, to treat or prevent a viral infection, expandantigen-specific Breg cells, TC1, CD4+T helper cells and/or CD8+cytotoxic T cells and/or disease generated, autoregulatory T cell and Bcell “memory” cells. The response may also involve activation of othercomponents.

The terms “inflammatory response” and “inflammation” as used hereinindicate the complex biological response of vascular tissues of anindividual to harmful stimuli, such as pathogens, damaged cells, orirritants, and includes secretion of cytokines and more particularly ofpro-inflammatory cytokines, i.e. cytokines which are producedpredominantly by activated immune cells and are involved in theamplification of inflammatory reactions. Exemplary pro-inflammatorycytokines include but are not limited to IL-1, IL-6, IL-10, TNF-α,IL-17, IL21, IL23, IL27 and TGF-β. Exemplary inflammations include acuteinflammation and chronic inflammation. Acute inflammation indicates ashort-term process characterized by the classic signs of inflammation(swelling, redness, pain, heat, and loss of function) due to theinfiltration of the tissues by plasma and leukocytes. An acuteinflammation typically occurs as long as the injurious stimulus ispresent and ceases once the stimulus has been removed, broken down, orwalled off by scarring (fibrosis). Chronic inflammation indicates acondition characterized by concurrent active inflammation, tissuedestruction, and attempts at repair. Chronic inflammation is notcharacterized by the classic signs of acute inflammation listed above.Instead, chronically inflamed tissue is characterized by theinfiltration of mononuclear immune cells (monocytes, macrophages,lymphocytes, and plasma cells), tissue destruction, and attempts athealing, which include angiogenesis and fibrosis. An inflammation can beinhibited in the sense of the present disclosure by affecting and inparticular inhibiting any one of the events that form the complexbiological response associated with an inflammation in an individual.

An autoimmune disorder may include, but is not limited to, diabetesmelitus, pre-diabetes, transplantation rejection, multiple sclerosis, amultiple-sclerosis related disorder, premature ovarian failure,scleroderm, Sjogren's disease, lupus, vilelego, alopecia (baldness),polyglandular failure, Grave's disease, hypothyroidism, polymyosititis,pemphigus, Crohn's disease, colititis, autoimmune hepatitis,hypopituitarism, myocardititis, Addison's disease, autoimmune skindiseases, uveitis, pernicious anemia, hypoparathyroidism, and/orrheumatoid arthritis. In certain aspects, a peptide component of anantigen/MHCII/particle complex is derived or designed from anautoantigen or an autoantigen epitope, or a mimic thereof, involved inthe autoimmune response to be probed, modulated, or blunted by thetreatment. In particular aspects, the autoantigen is a peptide,carbohydrate, or lipid. In certain aspects, an autoantigen is afragment, epitope, or peptide of a protein, carbohydrate, or lipidexpressed by certain cells of a subject, such as pancreatic beta cells,and include, but is not limited to a fragment of IGRP, Insulin, GAD orIA-2 protein. Various such proteins or epitopes have been identified fora variety of autoimmune conditions. The autoantigen may be a peptide,carbohydrate, lipid or the like derived from a second endocrine orneurocrine component, such as peri-islet Schwann cell or the like.

As used herein, the term “disease-relevant” antigen intends an antigenor fragment thereof selected to treat a selected disease. For example, adiabetes-relevant antigen is an antigen or fragment thereof that willtreat diabetes. A MS-relevant antigen is selected to treat MS. Adiabetes-relevant antigen would not be selected to treat MS. Similarly,an autoimmunity related antigen is an antigen that is relevant to anautoimmune disease and would not be selected for the treatment of adisorder or disease other than autoimmunity, e.g., cancer.

As used herein, the term “diabetes” intends a variable disorder ofcarbohydrate metabolism caused by a combination of hereditary andenvironmental factors and is usually characterized by inadequatesecretion or utilization of insulin, by excessive urine production, byexcessive amounts of sugar in the blood and urine, and by thirst,hunger, and loss of weight. Diabetes is characterized by Type 1 diabetesand Type 2 diabetes. The nonobese diabetic (“NOD”) mouse is an acceptedanimal model for the study and treatment of diabetes. Type 1 Diabetes(T1D) in mice is associated with autoreactive CD8+ T-cells. Nonobesediabetic (NOD) mice develop a form of T1D, closely resembling human T1D,that results from selective destruction of pancreatic β cells by T-cellsrecognizing a growing list of autoantigens. Although initiation of T1Dclearly requires the contribution of CD4+ cells, there is compellingevidence that T1D is CD8+ T-cell-dependent. It has been discovered thata significant fraction of islet-associated CD8+ cells in NOD mice useCDR3-invariant Vα17-Jα42+ TCRs, referred to as ‘8.3-TCR-like’. Thesecells, which recognize the mimotope NRP-A7 (defined using combinatorialpeptide libraries) in the context of the MHC molecule K^(d), are alreadya significant component of the earliest NOD islet CD8+ infiltrates, arediabetogenic, and target a peptide from islet-specificglucose-6-phosphatase catalytic subunit-related protein (IGRP), aprotein of unknown function. The CD8+ cells that recognize this peptide(IGRP₂₀₆₋₂₁₄, similar to NRP-A7) are unusually frequent in thecirculation (>1/200 CD8+ cells). Notably, progression of insulitis todiabetes in NOD mice is invariably accompanied by cyclic expansion ofthe circulating IGRP₂₀₆₋₂₁₄, reactive CD8+ pool, and by avid maturationof its islet-associated counterpart. More recently, it has been shownthat islet-associated CD8+ cells in NOD mice recognize multiple IGRPepitopes, indicating that IGRP is a dominant autoantigen for CD8+ cells,at least in murine T1D. NOD islet-associated CD8+ cells, particularlythose found early on in the disease process also recognize an insulinepitope (Ins B₁₅₋₂₃).

Association studies have suggested that certain HLA class I alleles(i.e., HLA-A*0201) afford susceptibility to human T1D. Pathology studieshave shown that the insulitis lesions of newly diagnosed patientsconsist mostly of (HLA class I-restricted) CD8+ T-cells, which are alsothe predominant cell population in patients treated by transplantationwith pancreas isografts (from identical twins) or allografts (fromrelated donors).

Insulin is a key target of the antibody and CD4+ response in both humanand murine T1D. The human insulin B chain epitope hInsB₁₀₋₁₈ ispresented by HLA-A*0201 to autoreactive CD8+ cells both in islettransplant recipients and in the course of spontaneous disease. Inaddition, four additional peptides have been identified from mousepre-proinsulin 1 or 2 that are recognized by islet-associated CD8+T-cells from HLA-A*0201-transgenic mice in the context of HLA-A*0201.

As used herein, the term “pre-diabetes” intends an asymptomatic periodpreceding a diabetic condition characterized by subclinical beta celldamage wherein the patient exhibits normal plasma glucose levels. Italso is characterized by the presence of islet cell autoantibodies(ICAs) and, when close to the onset of clinical symptoms, it may beaccompanied by intolerance to glucose.

As used herein, the term “multiple sclerosis” or “MS” intends theautoimmune disorder in which the body's immune system eats away at theprotective sheath that covers nerves. This interferes with thecommunication between the brain and the rest of the body. Ultimately,this may result in deterioration of the nerves themselves, a processthat is not reversible.

As used herein, the term “multiple sclerosis-related disorder” intends adisorder that co-presents with a susceptibility to MS or with MS.Non-limiting examples of such include neuromyelitis optica (NMO),uveitis, neuropathis pain sclerosis, atherosclerosis, arteriosclerosis,sclerosis disseminata systemic sclerosis, spino-optical MS, primaryprogressive MS (PPMS), and relapsing remitting MS (RRMS), progressivesystemic sclerosis, and ataxic sclerosis,

The terms “epitope” and “antigenic determinant” are used interchangeablyto refer to a site on an antigen to which B and/or T cells respond orrecognize. B-cell epitopes can be formed both from contiguous aminoacids or noncontiguous amino acids juxtaposed by tertiary folding of aprotein. Epitopes formed from contiguous amino acids are typicallyretained on exposure to denaturing solvents whereas epitopes formed bytertiary folding are typically lost on treatment with denaturingsolvents. An epitope typically includes at least 3, and more usually, atleast 5 or 8-20 amino acids in a unique spatial conformation. Methods ofdetermining spatial conformation of epitopes include, for example, x-raycrystallography and 2-dimensional nuclear magnetic resonance. See, e.g.,Glenn E. Morris, Epitope Mapping Protocols (1996). T-cells recognizecontinuous epitopes of about nine amino acids for CD8 cells or about13-15 amino acids for CD4 cells. T cells that recognize the epitope canbe identified by in vitro assays that measure antigen-dependentproliferation, as determined by ³H-thymidine incorporation by primed Tcells in response to an epitope (Burke et al., J. Inf. Dis.,170:1110-1119, 1994), by antigen-dependent killing (cytotoxic Tlymphocyte assay, Tigges et al., J. Immunol., 156(10):3901-3910, 1996)or by cytokine secretion. The presence of a cell-mediated immunologicalresponse can be determined by proliferation assays (CD4+ T cells) or CTL(cytotoxic T lymphocyte) assays.

Optionally, an antigen or preferably an epitope of an antigen, can bechemically conjugated to, or expressed as, a fusion protein with otherproteins, such as MHC and MHC related proteins.

As used herein, the terms “patient” and “subject” are used synonymouslyand refer to a mammal. In some embodiments the patient is a human. Inother embodiments the patient is a mammal commonly used in a laboratorysuch as a mouse, rat, simian, canine, feline, bovine, equine, or ovine.

As used in this application, the term “polynucleotide” refers to anucleic acid molecule that either is recombinant or has been isolatedfree of total genomic nucleic acid. Included within the term“polynucleotide” are oligonucleotides (nucleic acids 100 residues orless in length), recombinant vectors, including, for example, plasmids,cosmids, phage, viruses, and the like. Polynucleotides include, incertain aspects, regulatory sequences, isolated substantially away fromtheir naturally occurring genes or protein encoding sequences.Polynucleotides may be RNA, DNA, analogs thereof, or a combinationthereof. A nucleic acid encoding all or part of a polypeptide maycontain a contiguous nucleic acid sequence encoding all or a portion ofsuch a polypeptide of the following lengths: 10, 20, 30, 40, 50, 60, 70,80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220,230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360,370, 380, 390, 400, 410, 420, 430, 440, 441, 450, 460, 470, 480, 490,500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630,640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770,780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910,920, 930, 940, 950, 960, 970, 980, 990, 1000, 1010, 1020, 1030, 1040,1050, 1060, 1070, 1080, 1090, 1095, 1100, 1500, 2000, 2500, 3000, 3500,4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 9000, 10000, ormore nucleotides, nucleosides, or base pairs. It also is contemplatedthat a particular polypeptide from a given species may be encoded bynucleic acids containing natural variations that have slightly differentnucleic acid sequences but, nonetheless, encode the same orsubstantially similar protein, polypeptide, or peptide.

A polynucleotide is composed of a specific sequence of four nucleotidebases: adenine (A); cytosine (C); guanine (G); thymine (T); and uracil(U) for thymine when the polynucleotide is RNA. Thus, the term“polynucleotide sequence” is the alphabetical representation of apolynucleotide molecule. This alphabetical representation can be inputinto databases in a computer having a central processing unit and usedfor bioinformatics applications such as functional genomics and homologysearching.

The term “isolated” or “recombinant” as used herein with respect tonucleic acids, such as DNA or RNA, refers to molecules separated fromother DNAs or RNAs, respectively that are present in the natural sourceof the macromolecule as well as polypeptides. The term “isolated orrecombinant nucleic acid” is meant to include nucleic acid fragmentswhich are not naturally occurring as fragments and would not be found inthe natural state. The term “isolated” is also used herein to refer topolynucleotides, polypeptides and proteins that are isolated from othercellular proteins and is meant to encompass both purified andrecombinant polypeptides. In other embodiments, the term “isolated orrecombinant” means separated from constituents, cellular and otherwise,in which the cell, tissue, polynucleotide, peptide, polypeptide,protein, antibody or fragment(s) thereof, which are normally associatedin nature. For example, an isolated cell is a cell that is separatedfrom tissue or cells of dissimilar phenotype or genotype. An isolatedpolynucleotide is separated from the 3′ and 5′ contiguous nucleotideswith which it is normally associated in its native or naturalenvironment, e.g., on the chromosome. As is apparent to those of skillin the art, a non-naturally occurring polynucleotide, peptide,polypeptide, protein, antibody or fragment(s) thereof, does not require“isolation” to distinguish it from its naturally occurring counterpart.

A polynucleotide or polynucleotide region (or a polypeptide orpolypeptide region) having a certain percentage (for example, 80%, 85%,90%, or 95%) of “sequence identity” to another sequence means that, whenaligned, that percentage of bases (or amino acids) are the same incomparing the two sequences. The alignment and the percent homology orsequence identity can be determined using software programs known in theart, for example those described in Current Protocols in MolecularBiology (Ausubel et al., eds. 1987) Supplement 30, section 7.7.18, Table7.7.1. Preferably, default parameters are used for alignment. Apreferred alignment program is BLAST, using default parameters. Inparticular, preferred programs are BLASTN and BLASTP, using thefollowing default parameters: Genetic code=standard; filter =none;strand=both; cutoff=60; expect=10; Matrix=BLOSUM62; Descriptions=50sequences; sort by =HIGH SCORE; Databases=non-redundant,GenBank+EMBL+DDBJ+PDB+GenBank CDStranslations+SwissProtein+SPupdate+PIR. Details of these programs can befound at the following Internet address: ncbi.nlm.nih.gov/cgi-bin/BLAST.

It is to be inferred without explicit recitation and unless otherwiseintended, that when the present invention relates to an antigen,polypeptide, protein, polynucleotide or antibody, an equivalent or abiologically equivalent of such is intended within the scope of thisinvention. As used herein, the term “biological equivalent thereof” isintended to be synonymous with “equivalent thereof” when referring to areference antigen, protein, antibody, fragment, polypeptide or nucleicacid, and intends those having minimal homology while still maintainingdesired structure or functionality. Unless specifically recited herein,it is contemplated that any polynucleotide, polypeptide or proteinmentioned herein also includes equivalents thereof. In one aspect, anequivalent polynucleotide is one that hybridizes under stringentconditions to the polynucleotide or complement of the polynucleotide asdescribed herein for use in the described methods. In another aspect, anequivalent antibody or antigen binding polypeptide intends one thatbinds with at least 70%, or alternatively at least 75%, or alternativelyat least 80%, or alternatively at least 85%, or alternatively at least90%, or alternatively at least 95% affinity or higher affinity to areference antibody or antigen binding fragment. In another aspect, theequivalent thereof competes with the binding of the antibody or antigenbinding fragment to its antigen under a competitive ELISA assay. Inanother aspect, an equivalent intends at least about 80% homology oridentity and alternatively, at least about 85%, or alternatively atleast about 90%, or alternatively at least about 95%, or alternatively98% percent homology or identity and exhibits substantially equivalentbiological activity to the reference protein, polypeptide or nucleicacid.

“Hybridization” refers to a reaction in which one or morepolynucleotides react to form a complex that is stabilized via hydrogenbonding between the bases of the nucleotide residues. The hydrogenbonding may occur by Watson-Crick base pairing, Hoogstein binding, or inany other sequence-specific manner. The complex may comprise two strandsforming a duplex structure, three or more strands forming amulti-stranded complex, a single self-hybridizing strand, or anycombination of these. A hybridization reaction may constitute a step ina more extensive process, such as the initiation of a PC reaction, orthe enzymatic cleavage of a polynucleotide by a ribozyme.

Examples of stringent hybridization conditions include: incubationtemperatures of about 25° C. to about 37° C.; hybridization bufferconcentrations of about 6×SSC to about 10×SSC; formamide concentrationsof about 0% to about 25%; and wash solutions from about 4×SSC to about8×SSC. Examples of moderate hybridization conditions include: incubationtemperatures of about 40° C. to about 50° C.; buffer concentrations ofabout 9×SSC to about 2×SSC; formamide concentrations of about 30% toabout 50%; and wash solutions of about 5×SSC to about 2×SSC. Examples ofhigh stringency conditions include: incubation temperatures of about 55°C. to about 68° C.; buffer concentrations of about 1×SSC to about0.1×SSC; formamide concentrations of about 55% to about 75%; and washsolutions of about 1×SSC, 0.1×SSC, or deionized water. In general,hybridization incubation times are from 5 minutes to 24 hours, with 1,2, or more washing steps, and wash incubation times are about 1, 2, or15 minutes. SSC is 0.15 M NaCl and 15 mM citrate buffer. It isunderstood that equivalents of SSC using other buffer systems can beemployed.

“Homology” or “identity” or “similarity” refers to sequence similaritybetween two peptides or between two nucleic acid molecules. Homology canbe determined by comparing a position in each sequence which may bealigned for purposes of comparison. When a position in the comparedsequence is occupied by the same base or amino acid, then the moleculesare homologous at that position. A degree of homology between sequencesis a function of the number of matching or homologous positions sharedby the sequences. An “unrelated” or “non-homologous” sequence sharesless than 40% identity, or alternatively less than 25% identity, withone of the sequences of the present invention.

“Homology” or “identity” or “similarity” can also refer to two nucleicacid molecules that hybridize under stringent conditions.

As used herein, the terms “treating,” “treatment” and the like are usedherein to mean obtaining a desired pharmacologic and/or physiologiceffect. The effect may be therapeutic in terms of a partial or completecure for a disorder and/or adverse effect attributable to the disorder.In one aspect, treatment indicates a reduction in the signs of thedisease using an established scale.

IGRP, which is encoded by a gene (located on chromosome 2q28-32 thatoverlaps a T1D susceptibility locus, IDDM7 (2q31), has also beenrecently identified as a beta-cell autoantigen of potential relevance inhuman T1D. Two HLA-A*0201-binding epitopes of human IGRP (hIGRP₂₂₈₋₂₃₆and hIGRP₂₆₅₋₂₇₃) are recognized by islet-associated CD8+ cells frommurine MHC class I-deficient NOD mice expressing an HLA-A*0201transgene. Non-limited examples of IGRP antigens binding to the murineMHC class II molecule (IAg7) include for example, IGRP₂₀₆₋₂₁₄, whichcomprises the antigenic peptide VYLKTNVFL (SEQ ID NO: 4) and IGRP₄₋₂₂,which comprises the antigenic peptide LHRSGVLIIHHLQEDYRTY (SEQ ID NO:68) or an equivalent thereof, and IGRP₁₂₈₋₁₄₅, which comprises theantigenic peptide TAALSYTISRMEESSVTL (SEQ ID NO: 69) or an equivalentthereof.

“To prevent” intends to prevent a disorder or effect in vitro or in vivoin a system or subject that is predisposed to the disorder or effect.

A “composition” is intended to mean a combination of active agent andanother compound or composition, inert (for example, a detectable agentor label) or active, such as an adjuvant. In certain embodiments, thecomposition does not contain an adjuvant.

A “pharmaceutical composition” is intended to include the combination ofan active agent with a carrier, inert or active, making the compositionsuitable for diagnostic or therapeutic use in vitro, in vivo or ex vivo.

The term “functionally equivalent codon” is used herein to refer tocodons that encode the same amino acid, such as the six codons forarginine or serine, and also refers to codons that encode biologicallyequivalent amino acids (see below Table).

Codon Table Amino Acids Codons Alanine Ala A GCA GCC GCG GCU CysteineCys C UGC UGU Aspartic acid Asp D GAC GAU Glutamic acid Glu E GAA GAGPhenylalanine Phe F UUC UUU Glycine Gly G GGA GGC GGG GGU Histidine HisH CAC CAU Isoleucine He I AUA AUC AUU Lysine Lys K AAA AAG Leucine Leu LUUA UUG CUA CUC CUG CUU Methionine Met M AUG Asparagine Asn N AAC AAUProline Pro P CCA CCC CCG CCU Glutamine Gin Q CAA CAG Arginine Arg RAGA AGG CGA CGC CGG CGU Serine Ser s AGC AGU UCA UCC UCG UCU ThreonineThr T ACA ACC ACG ACI Valine Val V GUA GUC GUG GUU Tryptophan Trp W UGGTyrosine Tyr Y UAC UAU

As used herein, a “protein” or “polypeptide” or “peptide” refers to amolecule comprising at least five amino acid residues.

Other objects, features and advantages of the present invention willbecome apparent from the following detailed description. It should beunderstood, however, that the detailed description and the specificexamples, while indicating specific embodiments of the invention, aregiven by way of illustration only, since various changes andmodifications within the spirit and scope of the invention will becomeapparent to those skilled in the art from this detailed description.

II. DESCRIPTIVE EMBODIMENTS

There is currently no therapeutic platform that enables completesuppression of polyclonal autoimmune responses without compromisingsystemic immunity. Applicant's disclosure described herein enables thedesign of autoimmune disease-specific medicines that turn autoreactivedisease-specific CD4+ T-cells and B-cells into cognate, mono-specificregulatory CD4+ T-cells and B-cells that coordinately suppress all otherautoreactive T and B-cell responses of the host, regardless of theirfine antigenic specificity, and yet with exquisite disease-specificityand without impairing systemic immunity.

The Autoantigenic Complexity of Type 1 Diabetes (T1D).

T1D is caused by a chronic autoimmune response that progressively erodesthe pancreatic Beta-cell mass. B-cell destruction in both humans and NODmice is effected by T-cells recognizing many autoantigens (Tsai, S. etal. (2008) Adv. Immunol. 100:79-124; Lieberman, S. et al. (2003) TissueAntigens 62:359-377). Although the precise sequence of events remainsill defined, current evidence suggests that T1D requires CD4+ and CD8+cells; that autoreactive T cells differentiate into killers by engagingB-cell antigens on local APCs; and that these T-cells target a widerepertoire of autoantigens (Tsai, S. et al. (2008) Adv. Immunol.100:79-124; Santamaria, P. (2010) Immunity 32:437-445).

It has been shown that soluble peptides can induce peptide-specificT-cell tolerance in vivo, but cannot blunt poly-specific autoimmuneresponses (Han et al. (2005) Nature Medicine 11(6):645-652).Unexpectedly, it was found that, unlike therapy with soluble peptide,therapy with NPs coated with a single T1D-relevant pMHC class I(originally used as a negative control) blunted the progression of T1Din pre-diabetic NOD mice and restored normoglycemia in diabetic animals(Tsai, S. et al. (2010) Immunity 32:568-580). Subsequent work led to theunexpected discovery that pMHC-NP therapy functions by expanding, in anepitope-specific manner, autoantigen-experienced autoreactive CD8+ cellsthat suppressed the recruitment of other autoantigenic T cellspecificities by inhibiting and killing autoantigen-loaded APCs. Morerecently, Applicant has found that this therapeutic platform can beharnessed for the in vivo expansion of autoreactive T-regulatory CD4+cells. Specifically, Applicant discovered that NPs coated withindividual T1D-relevant pMHC class II expand disease-specific TR1 CD4+T-cells, expressing the TR1 markers CD49b and LAG3 (Gagliani, N. et al.(2013) Nature Medicine 19:739-746) and producing the cytokines IL10 andTGF-β (see below).

Collectively, these observations support a new paradigm in theprogression of autoimmunity, stating that chronic stimulation of naïveautoreactive CD8+ or CD4+ T cells by endogenous epitopes triggers theirdifferentiation into memory-like autoreactive regulatory T cells; andthat these memory autoreactive regulatory cells suppress the activationof both cognate and non-cognate high-avidity autoreactive T cellspecificities by suppressing and/or killing autoantigen-loaded APCs(Tsai, S. et al. (2010) Immunity 32:568-580). Importantly, and withoutbeing bound by theory, any single epitope (pMHC) specificity involved inan autoimmune disease (among many) can be used, when coated as a ligandonto NPs, to blunt complex autoimmune responses. It is Applicant'sbelief that these NP preparations cannot activate naïve T-cells, henceinduce effector T-cell responses, because they lack key co-stimulatorymolecules, such as CD80 and CD86. In fact, cognate naïve and effectorautoreactive cells are deleted by this approach. Therefore, thetherapeutic approach that enabled its discovery provide a platform for anew class of therapeutics in autoimmunity, potentially capable ofresolving polyclonal autoimmune responses in a disease- andorgan-specific manner without compromising systemic immunity.

III. METHODS

Medical and diagnostic methods are also provided. In one aspect, amethod is provided for promoting the formation, expansion andrecruitment of B-regulatory cells and/or TR1 cells (e.g., TR1 and CD4+cells) in an antigen-specific manner in a subject in need thereof,comprising, or alternatively consisting essentially of, or yet furtherconsisting of, administering to the subject an effective amount of theNP-complex or composition as described herein.

In another aspect, a method for treating or preventing an autoimmunedisease or disorder as described herein, e.g., MS, a MS-relateddisorder, diabetes or pre-diabetes, in a subject in need thereof isprovided, the method comprising, or alternatively consisting essentiallyof, or yet further consisting of, administering to the subject aneffective amount of the NP-complex or composition as described herein,wherein the autoantigen is disease-relevant for the disease to betreated, e.g., for the prevention or treatment of diabetes, the antigenis a diabetes-relevant antigen. In a further aspect, the autoimmunedisease is multiple-sclerosis or a multiple-sclerosis related disorderand the antigen is MS-relevant.

Peptide antigens for the treatment or prevention of pre-diabetes ordiabetes, include, but are not limited to hInsB₁₀₋₁₈ (HLVEALYLV (SEQ IDNO: 1)), hIGRP₂₂₈₋₂₃₆ (LNIDLLWSV (SEQ ID NO: 2)), hIGRP₂₆₅₋₂₇₃(VLFGLGFAI (SEQ ID NO: 3)), IGRP₂₀₆₋₂₁₄ (VYLKTNVFL (SEQ ID NO: 4)),NRP-A7 (KYNKANAFL (SEQ ID NO: 5)), NRP-I4 (KYNIANVFL (SEQ ID NO: 6)),NRP-V7 (KYNKANVFL (SEQ ID NO: 7)), YAI/D^(b) (FQDENYLYL (SEQ ID NO: 8))and/or INS B15-23 (LYLVCGERG (SEQ ID NO: 9)), GAD65₁₁₄₋₁₂₃, VMNILLQYVV(SEQ ID NO: 10); GAD65₅₃₆₋₅₄₅, RMMEYGTTMV (SEQ ID NO: 11); GFAP₁₄₃₋₁₅₁,NLAQTDLATV (SEQ ID NO: 12); GFAP₂₁₄₋₂₂₂, QLARQQVHV (SEQ ID NO: 13);IA-2₁₇₂₋₁₈₀, SLSPLQAEL (SEQ ID NO: 14); IA-2₄₈₂₋₄₉₀, SLAAGVKLL (SEQ IDNO: 15); IA-2₈₀₅₋₈₁₃, VIVMLTPLV (SEQ ID NO: 16); ppIAPP₅₋₁₃, KLQVFLIVL(SEQ ID NO: 17); ppIAPP₉₋₁₇, FLIVLSVAL (SEQ ID NO: 18); IGRP₁₅₂₋₁₆₀,FLWSVFMLI (SEQ ID NO: 19); IGRP₂₁₁₋₂₁₉, NLFLFLFAV (SEQ ID NO: 20);IGRP₂₁₅₋₂₂₃, FLFAVGFYL (SEQ ID NO: 21); IGRP₂₂₂₋₂₃₀, YLLLRVLNI (SEQ IDNO: 22); IGRP₂₂₈₋₂₃₆, LNIDLLWSV (SEQ ID NO: 23); IGRP₂₆₅₋₂₇₃, VLFGLGFAI(SEQ ID NO: 3); IGRP₂₉₃₋₃₀₁, RLLCALTSL (SEQ ID NO: 24);Pro-insulin_(L2-10), ALWMRLLPL (SEQ ID NO: 25); Pro-insulin_(L3-11),LWMRLLPLL (SEQ ID NO: 26); Pro-insulin_(L6-14), RLLPLLALL (SEQ ID NO:27); Pro-insulin_(B5-14), HLCGSHLVEA (SEQ ID NO: 28);Pro-insulin_(B10-18), HLVEALYLV (SEQ ID NO: 1); Pro-insulin_(B14-22),ALYLVCGER (SEQ ID NO: 29); Pro-insulin_(B15-24), LYLVCGERGF (SEQ ID NO:30); Pro-insulin_(B17-25), LVCGERGFF (SEQ ID NO: 31);Pro-insulin_(B18-27), VCGERGFFYT (SEQ ID NO: 32); Pro-insulin_(B20-27),GERGFFYT (SEQ ID NO: 33); Pro-insulin_(B21-29), ERGFFYTPK (SEQ ID NO:34); Pro-insulin_(B25-C1), FYTPKTRRE (SEQ ID NO: 35);Pro-insulin_(B27-C5), TPKTRREAEDL (SEQ ID NO: 36); Pro-insulin_(C20-28),SLQPLALEG (SEQ ID NO: 37); Pro-insulin_(C25-33), ALEGSLQKR (SEQ ID NO:38); Pro-insulin_(C29-A5), SLQKRGIVEQ (SEQ ID NO: 39);Pro-insulin_(A1-10), GIVEQCCTSI (SEQ ID NO: 40); Pro-insulin_(A2-10),IVEQCCTSI (SEQ ID NO: 41); Pro-insulin_(A12-20), SLYQLENYC (SEQ ID NO:42) or equivalents and/or combinations thereof. Additional examplesinclude ProIns 76-90, SLQPLALEGSLQKRG (SEQ ID NO: 43), ProIns 79-89,PLALEGSLQKR (SEQ ID NO: 44), ProIns 90-109, GIVEQCCTSICSLYQLENYC (SEQ IDNO: 45), ProIns 94-105, QCCTSICSLYQL (SEQ ID NO: 46), GAD 247-266,NMYAMMIARFKMFPEVKEKG (SEQ ID NO: 47), GAD 255-265, RFKMFPEVKEK (SEQ IDNO: 48), GAD 555-567, NFFRMVISNPAAT (SEQ ID NO: 49), IGRP 13-25,QHLQKDYRAYYTF (SEQ ID NO: 50), IGRP 8-27, GVLIIQHLQKDYRAYYTFLN (SEQ IDNO: 51), ProIns B24-C36, FFYTPMSRREVED (SEQ ID NO: 52) and equivalentsof each thereof.

Whent the method is directed to the treatment of MS or MS-relateddisorders, the complex includes antigens related to multiple sclerosis.Such antigens include, for example, those disclosed in U.S. PatentPublication No. 2012/0077686, and antigens derived from myelin basicprotein, myelin associated glycoprotein, myelin oligodendrocyte protein,proteolipid protein, oligodendrocyte myelin oligoprotein, myelinassociated oligodendrocyte basic protein, oligodendrocyte specificprotein, heat shock proteins, oligodendrocyte specific proteins NOGO A,glycoprotein Po, peripheral myelin protein 22, and 2′3′-cyclicnucleotide 3′-phosphodiesterase. In certain embodiments, the antigen isderived from Myelin Oligodendrocyte Glycoprotein (MOG). Non-limitedexamples include, for example, MAG₂₈₇₋₂₉₅, SLLLELEEV (SEQ ID NO: 53);MAG₅₀₉₋₅₁₇, LMWAKIGPV (SEQ ID NO: 54); MAG₅₅₆₋₅₆₄, VLFSSDFRI (SEQ ID NO:55); MBP₁₁₀₋₁₁₈, SLSRFSWGA (SEQ ID NO: 56); MOG₁₁₄₋₁₂₂, KVEDPFYWV (SEQID NO: 57); MOG₁₆₆₋₁₇₅, RTFDPHFLRV (SEQ ID NO: 58); MOG₁₇₂₋₁₈₀,FLRVPCWKI (SEQ ID NO: 59); MOG₁₇₉₋₁₈₈, KITLFVIVPV (SEQ ID NO: 60);MOG₁₈₈₋₁₉₆, VLGPLVALI (SEQ ID NO: 61); MOG₁₈₁₋₁₈₉, TLFVIVPVL (SEQ ID NO:62); MOG₂₀₅₋₂₁₄, RLAGQFLEEL (SEQ ID NO: 63); PLP₈₀₋₈₈, FLYGALLLA (SEQ IDNO: 64) or equivalents or combinations thereof.

Additional non-limiting examples of antigens that can be used in thisinvention comprise polypeptides comprising, or alternatively consistingessentially of, or yet further consisting of the polypeptides of thegroup: MOG₃₅₋₅₅, MEVGWYRSPFSRVVHLYRNGK (SEQ ID NO: 65) MOG₃₆₋₅₅,EVGWYRSPFSRVVHLYRNGK (SEQ ID NO: 66); MAG₂₈₇₋₂₉₅, SLLLELEEV (SEQ ID NO:53); MAG₅₀₉₋₅₁₇, LMWAKIGPV (SEQ ID NO: 54); MAG₅₅₆₋₅₆₄, VLFSSDFRI (SEQID NO: 55); MBPI₁₁₀₋₁₁₈, SLSRFSWGA (SEQ ID NO: 56); MOG₁₁₄₋₁₂₂,KVEDPFYWV (SEQ ID NO: 57); MOG₁₆₆₋₁₇₅, RTFDPHFLRV (SEQ ID NO: 58);MOG₁₇₂₋₁₈₀, FLRVPCWKI (SEQ ID NO: 59); MOG₁₇₉₋₁₈₈, KITLFVIVPV (SEQ IDNO: 60); MOG₁₈₈₋₁₉₆, VLGPLVALI (SEQ ID NO: 61); MOG₁₈₁₋₁₈₉, TLFVIVPVL(SEQ ID NO: 62); MOG₂₀₅₋₂₁₄, RLAGQFLEEL (SEQ ID NO: 63); PLP₈₀₋₈₈,FLYGALLLA (SEQ ID NO: 64), or an equivalent of each thereof, orcombinations thereof.

Methods to determine and monitor the therapy are known in the art andbriefly described herein. When delivered in vitro, administration is bycontacting the composition with the tissue or cell by any appropriatemethod, e.g., by administration to cell or tissue culture medium and isuseful as a screen to determine if the therapy is appropriate for anindividual or to screen for alternative therapies to be used as asubstitute or in combination with the disclosed compositions. Whenadministered in vivo, administration is by systemic or localadministration. In vivo, the methods can be practiced on a non-humananimal to screen alternative therapies to be used as a substitute or incombination with the disclosed compositions prior to humanadministration. In a human or non-human mammal, they are also useful totreat the disease or disorder.

The above methods require administration of an effective amount of aNP-complex.

The MHC of the antigen-MHC-nanoparticle complex can be MHC I, MHC II, ornon-classical MHC but preferably MHCII. MHC proteins are describedherein. In one embodiment, the MHC of the antigen-MHC-nanoparticlecomplex is a MHC class I. In another embodiment, the MHC is a MHC classII. In other embodiments, the MHC component of theantigen-MHC-nanoparticle complex is MHC class II or a non-classical MHCmolecule as described herein. In one aspect, the antigen comprises, oralternatively consists essentially of, or yet further consists of thepolypeptide GWYRSPFSRVVH (SEQ ID NO: 67) or an equivalent ofGWYRSPFSRVVH (SEQ ID NO: 67).

The size of the nanoparticle can range from about 1 nm to about 1 Incertain embodiments, the nanoparticle is less than about 1 μm indiameter. In other embodiments, the nanoparticle is less than about 500nm, less than about 400 nm, less than about 300 nm, less than about 200nm, less than about 100 nm, or less than about 50 nm in diameter. Infurther embodiments, the nanoparticle is from about 1 nm to about 10 nm,15 nm, 20 nm, 25 nm, 30 nm, 40 nm, 50 nm, 75 nm, or 100 nm in diameter.In specific embodiments, the nanoparticle is from about 1 nm to about100 nm, about 1 nm to about 50 nm, about 1 nm to about 20 nm, or about 5nm to about 20 nm.

The size of the complex can range from about 5 nm to about 1 In certainembodiments, the complex is less than about 1 μm or alternatively lessthan 100 nm in diameter. In other embodiments, the complex is less thanabout 500 nm, less than about 400 nm, less than about 300 nm, less thanabout 200 nm, less than about 100 nm, or less than about 50 nm indiameter. In further embodiments, the complex is from about 5 nm or 10nm to about 50 nm, or about 5 nm to about 75 nm, or about 5 nm to about50 nm, or about 5 nm to about 60 nm, or from about 10 nm to about 60 nm,or in one aspect about 55 nm.

Applicant has discovered that the density of the antigen-MHC complexeson the nanoparticle contributes to the therapeutic benefit. Thus, asdisclosed herein the antigen-MHC nanoparticle complex can have a defineddensity in the range of from about 0.05 MHC molecules per 100 nm² ofsurface area of the nanoparticle including the complex, assuming atleast 2 MHC, or alternatively at least 8, or alternatively at least 9,or alternatively at least 10, or alternatively at least 11, oralternatively at least 12, MHC complexed to the nanoparticle. In oneaspect the complex has a density of MHC from about 0.01 MHC per 100 nm²(0.05 MHC/100 nm²) to about 30 MHC/100 nm², or alternatively from 0.1MHC/100 nm² to about 25 MHC/100 nm², or alternatively from about 0.3MHC/100 nm² to about 25 MHC/100 nm², or alternatively from about 0.4MHC/100 nm² to about 25 MHC/100 nm², or alternatively from about 0.5MHC/100 nm² to about 20 MHC/100 nm², or alternatively from 0.6 MHC/100nm² to about 20 MHC/100 nm², or alternatively from about 1.0 MHC/100 nm²to about 20 MHC/100 nm², or alternatively from about 5.0 MHC/100 nm² toabout 20 MHC/100 nm², or alternatively from about 10.0 MHC/100 nm² toabout 20 MHC/100 nm², or alternatively from about 15 MHC/100 nm² toabout 20 MHC/100 nm², or alternatively at least about 0.5, oralternatively at least about 1.0, or alternatively at least about 5.0,or alternatively at least about 10.0, or alternatively at least about15.0 MHC/100 nm². In one aspect, when 9 or at least 9 MHC are complexedto a nanoparticle, the density range is from about 0.3 MHC/100 nm² toabout 20 MHC/100 nm².

In one of its method aspects, there is provided a method foraccumulating B-regulatory cells and/or anti-inflammatory T cells in apatient in need thereof. In a further embodiment, the T cell is a CD4+or CD8+ T cell. In a related embodiment, the T cell secretes IL-10 orTGFβ. The method comprises, consists essentially of, or yet furtherconsists of administering to a patient in need thereof an effectiveamount of the antigen-MHC nanoparticle complex as described herein.

In one embodiment, the compositions and methods described herein are fortreating an autoimmune disorder such as MS, MS-associated disorder,diabetes or pre-diabetes. The method comprises, consists essentially of,or yet further consists of administering to a patient in need thereof aneffective amount of the antigen-MHCII nanoparticle complex as describedherein.

Details regarding modes of administration in vitro and in vivo aredescribed within.

This disclosure also provides use of the NP-complexes for thepreparation of medicaments for the treatment and/or prevention ofdiseases and disorders as described herein.

IV. ANTIGEN-MHC-NANOPARTICLE COMPLEXES

A. Polypeptides and Polynucleotides

Further aspects relate to an isolated or purified polypeptide antigens,comprising, or consisting essentially of, or yet further consisting of,the amino acid sequences as described herein, or a polypeptide having atleast about 80% sequence identity, or alternatively at least 85%, oralternatively at least 90%, or alternatively at least 95%, oralternatively at least 98% sequence identity to the amino acid sequencesof the antigens, or polypeptides encoded by polynucleotides having atabout 80% sequence identity, or alternatively at least 85%, oralternatively at least 90%, or alternatively at least 95%, oralternatively at least 98% sequence identity to the polynucleotideencoding the amino acid sequences of the antigen, or its complement, ora polypeptide encoded by a polynucleotide that hybridizes underconditions of moderate to high stringency to a polynucleotide encodingthe amino acid sequence of the antigens, or its complement. Alsoprovided are isolated and purified polynucleotides encoding the antigenpolypeptides disclosed herein, or amino acids having at least about 80%sequence identity thereto, or alternatively at least 85%, oralternatively at least 90%, or alternatively at least 95%, oralternatively at least 98% sequence identity to the disclosed sequences,or an equivalent, or a polynucleotide that hybridizes under stringentconditions to the polynucleotide, its equivalent or its complement andisolated or purified polypeptides encoded by these polynucleotides. Thepolypeptides and polynucleotides can be combined with non-naturallyoccurring substances with which they are not associated with in nature,e.g., carriers, pharmaceutically acceptable carriers, vectors and MHCmolecules, nanoparticles as known in the art and as described herein.

Antigens, including segments, fragments and other molecules derived froman antigenic species, including but not limited to peptides,carbohydrates, lipids or other molecules presented by classical andnon-classical MHC molecules of the invention are typically complexed oroperatively coupled to a MHC molecule or derivative thereof. Antigenrecognition by T lymphocytes is major histocompatibility complex(MHC)-restricted. A given T lymphocyte will recognize an antigen onlywhen it is bound to a particular MHC molecule. In general, T lymphocytesare stimulated only in the presence of self-MHC molecules, and antigenis recognized as fragments of the antigen bound to self MHC molecules.MHC restriction defines T lymphocyte specificity in terms of the antigenrecognized and in terms of the MHC molecule that binds its antigenicfragment(s). In particular aspects certain antigens will be paired withcertain MHC molecules or polypeptides derived therefrom.

The term “operatively coupled” or “coated” as used herein, refers to asituation where individual polypeptide (e.g., MHC) and antigenic (e.g.,peptide) components are combined to form the active complex prior tobinding at the target site, for example, an immune cell. This includesthe situation where the individual polypeptide complex components aresynthesized or recombinantly expressed and subsequently isolated andcombined to form a complex, in vitro, prior to administration to asubject; the situation where a chimeric or fusion polypeptide (i.e.,each discrete protein component of the complex is contained in a singlepolypeptide chain) is synthesized or recombinantly expressed as anintact complex. Typically, polypeptide complexes are added to thenanoparticles to yield nanoparticles with adsorbed or coupledpolypeptide complexes having a ratio of number of molecules:number ofnanoparticle ratios from about, at least about or at most about 0.1,0.5, 1, 3, 5, 7, 10, 15, 20, 25, 30, 35, 40, 50, 100, 125, 150, 175,200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 600,700, 800, 900, 1000, 1500 or more to:1, more typically 0.1:1, 1:1 to50:1 or 300:1. The polypeptide content of the nanoparticles can bedetermined using standard techniques.

B. MHC Molecules

Intracellular and extracellular antigens present quite differentchallenges to the immune system, both in terms of recognition and ofappropriate response. Presentation of antigens to T cells is mediated bytwo distinct classes of molecules MHC class I (MHC-I) and MHC class II(MHC-II) (also identified as “pMHC” herein), which utilize distinctantigen processing pathways. Peptides derived from intracellularantigens are presented to CD8⁺ T cells by MHC class I molecules, whichare expressed on virtually all cells, while extracellularantigen-derived peptides are presented to CD4⁺ T cells by MHC-IImolecules. However, there are certain exceptions to this dichotomy.Several studies have shown that peptides generated from endocytosedparticulate or soluble proteins are presented on MHC-I molecules inmacrophages as well as in dendritic cells. In certain embodiments of theinvention, a particular antigen is identified and presented in theantigen-MHC-nanoparticle complex in the context of an appropriate MHCclass I or II polypeptide. In certain aspects, the genetic makeup of asubject may be assessed to determine which MHC polypeptide is to be usedfor a particular patient and a particular set of peptides. In certainembodiments, the MHC class 1 component comprises all or part of a HLA-A,HLA-B, HLA-C, HLA-E, HLA-F, HLA-G or CD-1 molecule. In embodimentswherein the MHC component is a MHC class II component, the MHC class IIcomponent can comprise all or a part of a HLA-DR, HLA-DQ, or HLA-DP.

Non-classical MHC molecules are also contemplated for use in MHCcomplexes of the invention. Non-classical MHC molecules arenon-polymorphic, conserved among species, and possess narrow, deep,hydrophobic ligand binding pockets. These binding pockets are capable ofpresenting glycolipids and phospholipids to Natural Killer T (NKT) cellsor certain subsets of CD8+ T-cells such as Qa1 or HLA-E-restricted CD8+T-cells. NKT cells represent a unique lymphocyte population thatco-express NK cell markers and a semi-invariant T cell receptor (TCR).They are implicated in the regulation of immune responses associatedwith a broad range of diseases.

C. Antigenic Components

Certain aspects of the invention include methods and compositionsconcerning antigenic compositions including segments, fragments, orepitopes of polypeptides, peptides, nucleic acids, carbohydrates, lipidsand other molecules that provoke or induce an antigenic response,generally referred to as antigens. In particular, antigenic segments orfragments of antigenic determinants, which lead to the destruction of acell via an autoimmune response, can be identified and used in making anantigen-MHC-nanoparticle complex described herein. Embodiments of theinvention include compositions and methods for the modulation of animmune response in a cell or tissue of the body.

Antigenic polypeptides and peptides of the invention may be modified byvarious amino acid deletions, insertions, and/or substitutions. Inparticular embodiments, modified polypeptides and/or peptides arecapable of modulating an immune response in a subject. In someembodiments, a wild-type version of a protein or peptide are employed,however, in many embodiments of the invention, a modified protein orpolypeptide is employed to generate an antigen-MHC-nanoparticle complex.An antigen-MHC-nanoparticle complex can be used to generate ananti-inflammatory immune response, to modify the T cell population ofthe immune system (i.e., re-educate the immune system), and/or fosterthe recruitment and accumulation of anti-inflammatory T cells to aparticular tissue. The terms described above may be used interchangeablyherein. A “modified protein” or “modified polypeptide” or “modifiedpeptide” refers to a protein or polypeptide whose chemical structure,particularly its amino acid sequence, is altered with respect to thewild-type protein or polypeptide. In some embodiments, a modifiedprotein or polypeptide or peptide has at least one modified activity orfunction (recognizing that proteins or polypeptides or peptides may havemultiple activities or functions). It is specifically contemplated thata modified protein or polypeptide or peptide may be altered with respectto one activity or function yet retains a wild-type activity or functionin other respects, such as immunogenicity or ability to interact withother cells of the immune system when in the context of anMHC-nanoparticle complex.

Non-limiting examples, of peptide antigens include, but are not limitedto hInsB₁₀₋₁₈ (HLVEALYLV (SEQ ID NO: 1)), hIGRP₂₂₈₋₂₃₆ (LNIDLLWSV (SEQID NO: 2)), hIGRP₂₆₅₋₂₇₃ (VLFGLGFAI (SEQ ID NO: 3)), IGRP₂₀₆₋₂₁₄(VYLKTNVFL (SEQ ID NO: 4)), NRP-A7 (KYNKANAFL (SEQ ID NO: 5)), NRP-I4(KYNIANVFL (SEQ ID NO: 6)), NRP-V7 (KYNKANVFL (SEQ ID NO: 7)), YAI/D^(b)(FQDENYLYL (SEQ ID NO: 8)) and/or INS B₁₅₋₂₃ (LYLVCGERG (SEQ ID NO: 9)),as well as peptides and proteins disclosed in U.S. Patent ApplicationPublication No. 2005/0202032 and equivalents and/or combinationsthereof.

In certain aspects, a peptide antigen for treatment of T1D isGAD65114-123, VMNILLQYVV (SEQ ID NO: 10); GAD65536-545, RMMEYGTTMV (SEQID NO: 11); GFAP₁₄₃₋₁₅₁, NLAQTDLATV (SEQ ID NO: 12); GFAP₂₁₄₋₂₂₂,QLARQQVHV (SEQ ID NO: 13); IA-2172-180, SLSPLQAEL (SEQ ID NO: 14);IA-2₄₈₂₋₄₉₀, SLAAGVKLL (SEQ ID NO: 15); IA-2₈₀₅₋₈₁₃, VIVMLTPLV (SEQ IDNO: 16); ppIAPP₅₋₁₃, KLQVFLIVL (SEQ ID NO: 17); ppIAPP₉₋₁₇, FLIVLSVAL(SEQ ID NO: 18); IGRP₁₅₂₋₁₆₀, FLWSVFMLI (SEQ ID NO: 19); IGRP₂₁₁₋₂₁₉,NLFLFLFAV (SEQ ID NO: 20); IGRP₂₁₅₋₂₂₃, FLFAVGFYL (SEQ ID NO: 21);IGRP₂₂₂₋₂₃₀, YLLLRVLNI (SEQ ID NO: 22); IGRP₂₂₈₋₂₃₆, LNIDLLWSV (SEQ IDNO: 23); IGRP₂₆₅₋₂₇₃, VLFGLGFAI (SEQ ID NO: 3); IGRP₂₉₃₋₃₀₁, RLLCALTSL(SEQ ID NO: 24); Pro-insulin_(L2-10), ALWMRLLPL (SEQ ID NO: 25);Pro-insulin_(L2-11), LWMRLLPLL (SEQ ID NO: 26); Pro-insulin_(L6-14),RLLPLLALL (SEQ ID NO: 27); Pro-insulin_(B5-14), HLCGSHLVEA (SEQ ID NO:28); Pro-insulin_(B10-18), HLVEALYLV (SEQ ID NO: 1);Pro-insulin_(B14-22), ALYLVCGER (SEQ ID NO: 29); Pro-insulin_(B15-24),LYLVCGERGF (SEQ ID NO: 30); Pro-insulin_(B17-25), LVCGERGFF (SEQ ID NO:31); Pro-insulin_(B18-27), VCGERGFFYT (SEQ ID NO: 32);Pro-insulin_(B20-27), GERGFFYT (SEQ ID NO: 33); Pro-insulin_(B21-29),ERGFFYTPK (SEQ ID NO: 34); Pro-insulin_(B25-C1), FYTPKTRRE (SEQ ID NO:35); Pro-insulin_(B27-C5), TPKTRREAEDL (SEQ ID NO: 36);Pro-insulin_(C20-28), SLQPLALEG (SEQ ID NO: 37); Pro-insulin_(C25-33),ALEGSLQKR (SEQ ID NO: 38); Pro-insulin_(C29-A5), SLQKRGIVEQ (SEQ ID NO:39); Pro-insulin_(A1-10), GIVEQCCTSI (SEQ ID NO: 40);Pro-insulin_(A2-10), IVEQCCTSI (SEQ ID NO: 41); Pro-insulin_(A12-20),SLYQLENYC (SEQ ID NO: 42) or equivalents and/or combinations thereof.

Additional non-limiting examples of antigens include MS and MS-relevantor related antigens that can be used in this invention comprisepolypeptides comprising, or alternatively consisting essentially of, oryet further consisting of the polypeptides of the group: MOG₃₅₋₅₅,MEVGWYRSPFSRVVHLYRNGK (SEQ ID NO: 65); MOG₃₆₋₅₅, EVGWYRSPFSRVVHLYRNGK(SEQ ID NO: 66): MAG₂₈₇₋₂₉₅, SLLLELEEV (SEQ ID NO: 53); MAG₅₀₉₋₅₁₇,LMWAKIGPV (SEQ ID NO: 54); MAG₅₅₆₋₅₆₄, VLFSSDFRI (SEQ ID NO: 55);MBPI₁₁₀₋₁₁₈, SLSRFSWGA (SEQ ID NO: 56); MOG₁₁₄₋₁₂₂, KVEDPFYWV (SEQ IDNO: 57); MOG₁₆₆₋₁₇₅, RTFDPHFLRV (SEQ ID NO: 58); MOG₁₇₂₋₁₈₀, FLRVPCWKI(SEQ ID NO: 59); MOG₁₇₉₋₁₈₈, KITLFVIVPV (SEQ ID NO: 60); MOG₁₈₈₋₁₉₆,VLGPLVALI (SEQ ID NO: 61); MOG₁₈₁₋₁₈₉, TLFVIVPVL (SEQ ID NO: 62);MOG₂₀₅₋₂₁₄, RLAGQFLEEL (SEQ ID NO: 63); PLP₈₀₋₈₈, FLYGALLLA (SEQ ID NO:64), or an equivalent of each thereof, or combinations thereof.

In still further aspects peptide antigens for the treatment of MS andMS-related disorders include without limitation: MOG₃₅₋₅₅,MEVGWYRSPFSRVVHLYRNGK (SEQ ID NO: 65); MOG₃₆₋₅₅, EVGWYRSPFSRVVHLYRNGK(SEQ ID NO: 66) MAG₂₈₇₋₂₉₅, SLLLELEEV (SEQ ID NO: 53); MAG₅₀₉₋₅₁₇,LMWAKIGPV (SEQ ID NO: 54); MAG₅₅₆₋₅₆₄, VLFSSDFRI (SEQ ID NO: 55);MBP₁₁₀₋₁₁₈, SLSRFSWGA (SEQ ID NO: 56); MOG₁₁₄₋₁₂₂, KVEDPFYWV (SEQ ID NO:57); MOG₁₆₆₋₁₇₅, RTFDPHFLRV (SEQ ID NO: 58); MOG₁₇₂₋₁₈₀, FLRVPCWKI (SEQID NO: 59); MOG₁₇₉₋₁₈₈, KITLFVIVPV (SEQ ID NO: 60); MOG₁₈₈₋₁₉₆,VLGPLVALI (SEQ ID NO: 61); MOG₁₈₁₋₁₈₉, TLFVIVPVL (SEQ ID NO: 62);MOG₂₀₅₋₂₁₄, RLAGQFLEEL (SEQ ID NO: 63); PLP₈₀₋₈₈, FLYGALLLA (SEQ ID NO:64) MAG₂₈₇₋₂₉₅, SLLLELEEV (SEQ ID NO: 53); MAG₅₀₉₋₅₁₇, LMWAKIGPV (SEQ IDNO: 54); MAG₅₅₆₋₅₆₄, VLFSSDFRI (SEQ ID NO: 55), and equivalents and/orcombinations thereof.

Antigens for the treatment of MS and MS-related disorders include, thosedisclosed in U.S. Patent Application Publication No. 2012/0077686, andantigens derived from myelin basic protein, myelin associatedglycoprotein, myelin oligodendrocyte protein, proteolipid protein,oligodendrocyte myelin oligoprotein, myelin associated oligodendrocytebasic protein, oligodendrocyte specific protein, heat shock proteins,oligodendrocyte specific proteins NOGO A, glycoprotein Po, peripheralmyelin protein 22, and 2′3′-cyclic nucleotide 3′-phosphodiesterase. Incertain embodiments, the antigen is derived from Myelin OligodendrocyteGlycoprotein (MOG).

In certain embodiments, the size of a protein or polypeptide (wild-typeor modified), including any complex of a protein or peptide of interestand in particular a MHC-peptide fusion, may comprise, but is not limitedto 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40,41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58,59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76,77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94,95, 96, 97, 98, 99, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190,200, 210, 220, 230, 240, 250, 275, 300, 325, 350, 375, 400, 425, 450,475, 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775, 800,825, 850, 875, 900, 925, 950, 975, 1000, 1100, 1200, 1300, 1400, 1500,1750, 2000, 2250, 2500 amino molecules or greater, including any rangeor value derivable therein, or derivative thereof. In certain aspects,5, 6, 7, 8, 9, 10 or more contiguous amino acids, including derivativesthereof, and fragments of an antigen, such as those amino acid sequencesdisclosed and referenced herein, can be used as antigens. It iscontemplated that polypeptides may be mutated by truncation, renderingthem shorter than their corresponding wild-type form, but also theymight be altered by fusing or conjugating a heterologous proteinsequence with a particular function (e.g., for presentation as a proteincomplex, for enhanced immunogenicity, etc.).

Proteinaceous compositions may be made by any technique known to thoseof skill in the art, including (i) the expression of proteins,polypeptides, or peptides through standard molecular biologicaltechniques, (ii) the isolation of proteinaceous compounds from naturalsources, or (iii) the chemical synthesis of proteinaceous materials. Thenucleotide as well as the protein, polypeptide, and peptide sequencesfor various genes have been previously disclosed, and may be found inthe recognized computerized databases. One such database is the NationalCenter for Biotechnology Information's GenBank and GenPept databases (onthe World Wide Web at ncbi.nlm.nih.gov/). The all or part of the codingregions for these genes may be amplified and/or expressed using thetechniques disclosed herein or as would be known to those of ordinaryskill in the art.

Amino acid sequence variants of autoantigenic epitopes and otherpolypeptides of these compositions can be substitutional, insertional,or deletion variants. A modification in a polypeptide of the inventionmay affect 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35,36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53,54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71,72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89,90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 100, 101, 102, 103, 104,105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118,119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132,133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146,147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160,161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174,175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188,189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202,203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216,217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230,231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 235, 236,237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250,251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264,265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278,279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292,293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306,307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320,321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334,335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348,349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362,363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376,377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390,391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404,405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418,419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432,433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446,447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460,461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474,475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488,489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500 or morenon-contiguous or contiguous amino acids of a peptide or polypeptide, ascompared to wild-type.

Deletion variants typically lack one or more residues of the native orwild-type amino acid sequence. Individual residues can be deleted or anumber of contiguous amino acids can be deleted. A stop codon may beintroduced (by substitution or insertion) into an encoding nucleic acidsequence to generate a truncated protein. Insertional mutants typicallyinvolve the addition of material at a non-terminal point in thepolypeptide. This may include the insertion of one or more residues.Terminal additions, called fusion proteins, may also be generated.

Substitutional variants typically contain the exchange of one amino acidfor another at one or more sites within the protein, and may be designedto modulate one or more properties of the polypeptide, with or withoutthe loss of other functions or properties. Substitutions may beconservative, that is, one amino acid is replaced with one of similarshape and charge. Conservative substitutions are well known in the artand include, for example, the changes of: alanine to serine; arginine tolysine; asparagine to glutamine or histidine; aspartate to glutamate;cysteine to serine; glutamine to asparagine; glutamate to aspartate;glycine to proline; histidine to asparagine or glutamine; isoleucine toleucine or valine; leucine to valine or isoleucine; lysine to arginine;methionine to leucine or isoleucine; phenylalanine to tyrosine, leucineor methionine; serine to threonine; threonine to serine; tryptophan totyrosine; tyrosine to tryptophan or phenylalanine; and valine toisoleucine or leucine. Alternatively, substitutions may benon-conservative such that a function or activity of a polypeptide orpeptide is affected, such as avidity or affinity for a cellularreceptor(s). Non-conservative changes typically involve substituting aresidue with one that is chemically dissimilar, such as a polar orcharged amino acid for a nonpolar or uncharged amino acid, and viceversa.

Proteins of the invention may be recombinant, or synthesized in vitro.Alternatively, a recombinant protein may be isolated from bacteria orother host cell.

It also will be understood that amino acid and nucleic acid sequencesmay include additional residues, such as additional N- or C-terminalamino acids, or 5′ or 3′ nucleic acid sequences, respectively, and yetstill be essentially as set forth in one of the sequences disclosedherein, so long as the sequence meets the criteria set forth above,including the maintenance of biological protein activity (e.g.,immunogenicity). The addition of terminal sequences particularly appliesto nucleic acid sequences that may, for example, include variousnon-coding sequences flanking either of the 5′ or 3′ portions of thecoding region.

It is contemplated that in compositions of the invention, there isbetween about 0.001 mg and about 10 mg of total protein per ml. Thus,the concentration of protein in a composition can be about, at leastabout or at most about 0.001, 0.010, 0.050, 0.1, 0.2, 0.3, 0.4, 0.5,0.6, 0.7, 0.8, 0.9, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5,6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0, 50, 100 μg/ml or mg/ml ormore (or any range derivable therein). Of this, about, at least about,or at most about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34,35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52,53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70,71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88,89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% may beantigen-MHC-nanoparticle complex.

In addition, U.S. Pat. No. 4,554,101 (Hopp), which is incorporatedherein by reference, teaches the identification and preparation ofepitopes from primary amino acid sequences on the basis ofhydrophilicity. Through the methods disclosed in Hopp, one of skill inthe art would be able to identify potential epitopes from within anamino acid sequence and confirm their immunogenicity. Numerousscientific publications have also been devoted to the prediction ofsecondary structure and to the identification of epitopes, from analysesof amino acid sequences (Chou & Fasman, Adv. Enzymol., 47:45-148, 1978;Chous and Fasman, Annu, Rev. Biochem., 47:251-276, 1978, Chou andFasman, Biochemistry, 13(2):211-222, 1974; Chau and Fasman,Biochemistry, 13(2):222-245, 1974, Chou and Fasman, Biophys. J.,26(3):385-399, 1979). Any of these may be used, if desired, tosupplement the teachings of Hopp in U.S. Pat. No. 4,554,101.

For any given autoimmune disease the antigen MHC complex can beidentified and pre-selected using known methods in the art. Algorithmsexist—derived from a set of aligned peptides known to bind to a givenMHC molecule, which can be used as a predictor of both peptide-MHCbinding and T-cell epitopes. See, e.g., Reche and Reinherz (2007)Methods Mol. Biol. 409:185-200.

Molecules other than peptides can be used as antigens or antigenicfragments in complex with MHC molecules, such molecules include, but arenot limited to carbohydrates, lipids, small molecules, and the like.Carbohydrates are major components of the outer surface of a variety ofcells. Certain carbohydrates are characteristic of different stages ofdifferentiation and very often these carbohydrates are recognized byspecific antibodies. Expression of distinct carbohydrates can berestricted to specific cell types.

D. Substrates/Nanoparticles

In certain aspect, antigen/MHC complexes are operatively coupled to asubstrate which can be bound covalently or non-covalently to thesubstrate. A substrate can be in the form of a nanoparticle thatoptionally comprises a biocompatible and/or bioabsorbable material.Accordingly, in one embodiment, the nanoparticle is biocompatible and/orbioabsorbable. In another aspect, the nanoparticle has a solid coreand/or is not a liposome. A substrate can also be in the form of ananoparticle such as those described previously in U.S. PatentPublication No. 2009/0155292. Nanoparticles can have a structure ofvariable dimension and known variously as a nanosphere, a nanoparticleor a biocompatible biodegradable nanosphere or a biocompatiblebiodegradable nanoparticle. Such particulate formulations containing anantigen/MHC complex can be formed by covalent or non-covalent couplingof the complex to the nanoparticle.

The nanoparticles typically consist of a substantially spherical coreand optionally one or more layers. The core may vary in size andcomposition. In addition to the core, the nanoparticle may have one ormore layers to provide functionalities appropriate for the applicationsof interest. The thicknesses of layers, if present, may vary dependingon the needs of the specific applications. For example, layers mayimpart useful optical properties.

Layers may also impart chemical or biological functionalities, referredto herein as chemically active or biologically active layers, and forthese functionalities the layer or layers may typically range inthickness from about 0.001 micrometers (1 nanometer) to about 10micrometers or more (depending on the desired nanoparticle diameter),these layers typically being applied on the outer surface of thenanoparticle.

The compositions of the core and layers may vary. Suitable materials forthe particles or the core include, but are not limited to polymers,ceramics, glasses, minerals, and the like. Examples include, but are notlimited to, standard and specialty glasses, silica, polystyrene,polyester, polycarbonate, acrylic polymers, polyacrylamide,polyacrylonitrile, polyamide, fluoropolymers, silicone, celluloses,silicon, metals (e.g., iron, gold, silver), minerals (e.g., ruby),nanoparticles (e.g., gold nanoparticles, colloidal particles, metaloxides, metal sulfides, metal selenides, and magnetic materials such asiron oxide), and composites thereof. The core could be of homogeneouscomposition, or a composite of two or more classes of material dependingon the properties desired. In certain aspects, metal nanoparticles willbe used. These metal particles or nanoparticles can be formed from Au,Pt, Pd, Cu, Ag, Co, Fe, Ni, Mn, Sm, Nd, Pr, Gd, Ti, Zr, Si, and In,precursors, their binary alloys, their ternary alloys and theirintermetallic compounds. See U.S. Pat. No. 6,712,997. In certainembodiments, the compositions of the core and layers may vary providedthat the nanoparticles are biocompatible and bioabsorbable. The corecould be of homogeneous composition, or a composite of two or moreclasses of material depending on the properties desired. In certainaspects, metal nanospheres will be used. These metal nanoparticles canbe formed from Fe, Ca, Ga and the like. In certain embodiments, thenanoparticle comprises a core comprising metal or metal oxide such asgold or iron oxide.

As previously stated, the nanoparticle may, in addition to the core,include one or more layers. The nanoparticle may include a layerconsisting of a biodegradable sugar or other polymer. Examples ofbiodegradable layers include but are not limited to dextran;poly(ethylene glycol); poly(ethylene oxide); mannitol; poly(esters)based on polylactide (PLA), polyglycolide (PGA), polycaprolactone (PCL);poly(hydroxalkanoate)s of the PHB-PHV class; and other modifiedpoly(saccharides) such as starch, cellulose and chitosan. Additionally,the nanoparticle may include a layer with suitable surfaces forattaching chemical functionalities for chemical binding or couplingsites.

Layers can be produced on the nanoparticles in a variety of ways knownto those skilled in the art. Examples include sol-gel chemistrytechniques such as described in Iler, Chemistry of Silica, John Wiley &Sons, 1979; Brinker and Scherer, Sol-gel Science, Academic Press,(1990). Additional approaches to producing layers on nanoparticlesinclude surface chemistry and encapsulation techniques such as describedin Partch and Brown, J. Adhesion, 67:259-276, 1998; Pekarek et al.,Nature, 367:258, (1994); Hanprasopwattana, Langmuir, 12:3173-3179,(1996); Davies, Advanced Materials, 10:1264-1270, (1998); and referencestherein. Vapor deposition techniques may also be used; see for exampleGolman and Shinohara, Trends Chem. Engin., 6:1-6, (2000); and U.S. Pat.No. 6,387,498. Still other approaches include layer-by-layerself-assembly techniques such as described in Sukhorukov et al.,Polymers Adv. Tech., 9(10-11):759-767, (1998); Caruso et al.,Macromolecules, 32(7):2317-2328, (1998); Caruso et al., J. Amer. Chem.Soc., 121(25):6039-6046, (1999); U.S. Pat. No. 6,103,379 and referencescited therein.

Nanoparticles may be formed by contacting an aqueous phase containingthe antigen/MHC/co-stimulatory molecule complex and a polymer and anonaqueous phase followed by evaporation of the nonaqueous phase tocause the coalescence of particles from the aqueous phase as taught inU.S. Pat. No. 4,589,330 or 4,818,542. Preferred polymers for suchpreparations are natural or synthetic copolymers or polymers selectedfrom the group consisting of gelatin agar, starch, arabinogalactan,albumin, collagen, polyglycolic acid, polylactic acid, glycolide-L(−)lactide poly(episilon-caprolactone, poly(epsilon-caprolactone-CO-lacticacid), poly(epsilon-caprolactone-CO-glycolic acid), poly(β-hydroxybutyric acid), poly(ethylene oxide), polyethylene,poly(alkyl-2-cyanoacrylate), poly(hydroxyethyl methacrylate),polyamides, poly(amino acids), poly(2-hydroxyethyl DL-aspartamide),poly(ester urea), poly(L-phenylalanine/ethyleneglycol/1,6-diisocyanatohexane) and poly(methyl methacrylate).Particularly preferred polymers are polyesters, such as polyglycolicacid, polylactic acid, glycolide-L(−) lactidepoly(episilon-caprolactone), poly(epsilon-caprolactone-CO-lactic acid),and poly(epsilon-caprolactone-CO-glycolic acid). Solvents useful fordissolving the polymer include: water, hexafluoroisopropanol,methylenechloride, tetrahydrofuran, hexane, benzene, orhexafluoroacetone sesquihydrate.

The size of the nanoparticle can range from about 1 nm to about 1 μm. Incertain embodiments, the nanoparticle is less than about 1 μm indiameter. In other embodiments, the nanoparticle is less than about 500nm, less than about 400 nm, less than about 300 nm, less than about 200nm, less than about 100 nm, or less than about 50 nm in diameter. Infurther embodiments, the nanoparticle is from about 1 nm to about 10 nm,15 nm, 20 nm, 25 nm, 30 nm, 40 nm, 50 nm, 75 nm, or 100 nm in diameter.In specific embodiments, the nanoparticle is from about 1 nm to about100 nm, about 1 nm to about 50 nm, about 1 nm to about 20 nm, or about 5nm to about 20 nm.

The size of the complex can range from about 5 nm to about 1 μm. Incertain embodiments, the complex is less than about 1 μm oralternatively less than 100 nm in diameter. In other embodiments, thecomplex is less than about 500 nm, less than about 400 nm, less thanabout 300 nm, less than about 200 nm, less than about 100 nm, or lessthan about 50 nm in diameter. In further embodiments, the complex isfrom about 10 nm to about 50 nm, or about 20 nm to about 75 nm, or about25 nm to about 60 nm, or from about 30 nm to about 60 nm, or in oneaspect about 55 nm.

E. Coupling Antigen-MHC Complex with the Nanoparticle

In order to couple the substrate or nanospheres to the antigen-MHCcomplexes the following techniques can be applied.

The binding can be generated by chemically modifying the substrate ornanoparticle which typically involves the generation of “functionalgroups” on the surface, said functional groups being capable of bindingto an antigen-MHC complex, and/or linking the optionally chemicallymodified surface of the substrate or nanoparticle with covalently ornon-covalently bonded so-called “linking molecules,” followed byreacting the antigen-MHC complex with the nanoparticles obtained.

The term “linking molecule” means a substance capable of linking withthe substrate or nanoparticle and also capable of linking to anantigen-MHC complex. In certain embodiments, the antigen-MHC complexesare coupled to the nanoparticle by a linker. Non-limiting examples ofsuitable linkers include dopamine (DPA)-polyethylene glycol (PEG)linkers such as DPA-PEG-NHS ester, DPA-PEG-orthopyridyl-disulfide (OPSS)and/or DPA-PEG-Azide. Other linkers include peptide linkers, ethyleneglycol, biotin, and strepdavidin.

The term “functional groups” as used herein before is not restricted toreactive chemical groups forming covalent bonds, but also includeschemical groups leading to an ionic interaction or hydrogen bonds withthe antigen-MHC complex. Moreover, it should be noted that a strictdistinction between “functional groups” generated at the surface andlinking molecules bearing “functional groups” is not possible, sincesometimes the modification of the surface requires the reaction ofsmaller linking molecules such as ethylene glycol with the nanospheresurface.

The functional groups or the linking molecules bearing them may beselected from amino groups, carbonic acid groups, thiols, thioethers,disulfides, guanidino, hydroxyl groups, amine groups, vicinal diols,aldehydes, alpha-haloacetyl groups, mercury organyles, ester groups,acid halide, acid thioester, acid anhydride, isocyanates,isothiocyanates, sulfonic acid halides, imidoesters, diazoacetates,diazonium salts, 1,2-diketones, phosphonic acids, phosphoric acidesters, sulfonic acids, azolides, imidazoles, indoles, N-maleimides,alpha-beta-unsaturated carbonyl compounds, arylhalogenides or theirderivatives.

Non-limiting examples for other linking molecules with higher molecularweights are nucleic acid molecules, polymers, copolymers, polymerizablecoupling agents, silica, proteins, and chain-like molecules having asurface with the opposed polarity with respect to the substrate ornanoparticle. Nucleic acids can provide a link to affinity moleculescontaining themselves nucleic acid molecules, though with acomplementary sequence with respect to the linking molecule.

A specific example of a covalent linker includes poly(ethylene) glycol(PEG) such as functionalized PEGs. As used herein, “functionalized PEGs”refer to PEG moieties including terminal functional group, non-limitingexamples of which include amino, mercapto, thioether, carboxyl, and thelikes. Non-limiting examples of functionalized PEG linkers on variousnanoparticle cores are provided in Tables 1 and 2 attached hereto, e.g.,the PEG linker thiol-PEG-NH₂ linker.

In certain embodiments, the linker as described herein has a definedsize. In some embodiments, the linker is less that about 10 kD, lessthan about 5 kD, less than about 4.5 kD, less than about 4 kD, less thanabout 3.5 kD, less than about 3 kD, less than about 2.5 kD, less thanabout 2 kD, or less than about 1 kD. In further embodiments, the linkeris from about 0.5 kD to about 5, 4.5, 4, 3.5, 3, 2.5, 2, 1.5, or 1 kD.In yet further embodiments, the linker is from about 1 to about, 4.5, 4,3.5, 3, 2.5, 2, or 1.5 kD.

As examples for polymerizable coupling agents, diacetylene, styrenebutadiene, vinylacetate, acrylate, acrylamide, vinyl compounds, styrene,silicone oxide, boron oxide, phosphorous oxide, borates, pyrrole,polypyrrole and phosphates can be cited.

The surface of the substrate or nanoparticle can be chemically modified,for instance by the binding of phosphonic acid derivatives havingfunctional reactive groups. One example of these phosphonic acid orphosphonic acid ester derivates is imino-bis(methylenphosphono) carbonicacid which can be synthesized according to the “Mannich-Moedritzer”reaction. This binding reaction can be performed with substrate ornanosphere as directly obtained from the preparation process or after apre-treatment (for instance with trimethylsilyl bromide). In the firstcase the phosphonic acid (ester) derivative may for instance displacecomponents of the reaction medium which are still bound to the surface.This displacement can be enhanced at higher temperatures. Trimethylsilylbromide, on the other hand, is believed to dealkylate alkylgroup-containing phosphorous-based complexing agents, thereby creatingnew binding sites for the phosphonic acid (ester) derivative. Thephosphonic acid (ester) derivative, or linking molecules bound thereto,may display the same functional groups as given above. A further exampleof the surface treatment of the substrate or nanosphere involves heatingin a diole such as ethylene glycol. It should be noted that thistreatment may be redundant if the synthesis already proceeded in a diol.Under these circumstances the synthesis product directly obtained islikely to show the necessary functional groups. This treatment ishowever applicable to substrate or nanoparticle that were produced in N-or P-containing complexing agents. If such substrate or particle aresubjected to an after-treatment with ethylene glycol, ingredients of thereaction medium (e.g. complexing agent) still binding to the surface canbe replaced by the diol and/or can be dealkylated.

It is also possible to replace N-containing complexing agents stillbound to the particle surface by primary amine derivatives having asecond functional group. The surface of the substrate or nanoparticlecan also be coated with silica. Silica allows a relatively simplechemical conjugation of organic molecules since silica easily reactswith organic linkers, such as triethoxysilane or chlorosilane. Thenanoparticle surface may also be coated by homo- or copolymers. Examplesfor polymerizable coupling agents areN-(3-aminopropyl)-3-mercaptobenzamidine,3-(trimethoxysilyl)propylhydrazide and3-trimethoxysilyl)propylmaleimide. Other non-limiting examples ofpolymerizable coupling agents are mentioned herein. These couplingagents can be used singly or in combination depending on the type ofcopolymer to be generated as a coating.

Another surface modification technique that can be used with substratesor nanoparticles containing oxidic transition metal compounds isconversion of the oxidic transition metal compounds by chlorine gas ororganic chlorination agents to the corresponding oxychlorides. Theseoxychlorides are capable of reacting with nucleophiles, such as hydroxyor amino groups as often found in biomolecules. This technique allowsgenerating a direct conjugation with proteins, for instance-via theamino group of lysine side chains. The conjugation with proteins aftersurface modification with oxychlorides can also be effected by using abi-functional linker, such as maleimidopropionic acid hydrazide.

For non-covalent linking techniques, chain-type molecules having apolarity or charge opposite to that of the substrate or nanospheresurface are particularly suitable. Examples for linking molecules whichcan be non-covalently linked to core/shell nanospheres involve anionic,cationic or zwitter-ionic surfactants, acidic or basic proteins,polyamines, polyamides, polysulfone or polycarboxylic acid. Thehydrophobic interaction between substrate or nanosphere and amphiphilicreagent having a functional reactive group can generate the necessarylink. In particular, chain-type molecules with amphiphilic character,such as phospholipids or derivatized polysaccharides, which can becrosslinked with each other, are useful. The absorption of thesemolecules on the surface can be achieved by coincubation. The bindingbetween affinity molecule and substrate or nanoparticle can also bebased on non-covalent, self-organising bonds. One example thereofinvolves simple detection probes with biotin as linking molecule andavidin- or strepdavidin-coupled molecules.

Protocols for coupling reactions of functional groups to biologicalmolecules can be found in the literature, for instance in “BioconjugateTechniques” (Greg T. Hermanson, Academic Press 1996). The biologicalmolecule (e.g., MHC molecule or derivative thereof) can be coupled tothe linking molecule, covalently or non-covalently, in line withstandard procedures of organic chemistry such as oxidation,halogenation, alkylation, acylation, addition, substitution oramidation. These methods for coupling the covalently or non-covalentlybound linking molecule can be applied prior to the coupling of thelinking molecule to the substrate or nanosphere or thereafter. Further,it is possible, by means of incubation, to effect a direct binding ofmolecules to correspondingly pre-treated substrate or nanoparticle (forinstance by trimethylsilyl bromide), which display a modified surfacedue to this pre-treatment (for instance a higher charge or polarsurface).

F. Protein Production

The present invention describes polypeptides, peptides, and proteins foruse in various embodiments of the present invention. For example,specific peptides and their complexes are assayed for their abilities toelicit or modulate an immune response. In specific embodiments, all orpart of the peptides or proteins of the invention can also besynthesized in solution or on a solid support in accordance withconventional techniques. Various automatic synthesizers are commerciallyavailable and can be used in accordance with known protocols. See, forexample, Stewart and Young, Solid Phase Peptide Synthesis, 2^(nd) Ed.,Pierce Chemical Co.l, (1984); Tam et al., J. Am. Chem. Soc., 105:6442,(1983); Merrifield, Science, 232(4748):341-347, (1986); and Barany andMerrifield, The Peptides, Gross and Meinhofer (Eds.), Academic Press,NY, 1-284, (1979), each incorporated herein by reference. Alternatively,recombinant DNA technology may be employed wherein a nucleotide sequencewhich encodes a peptide of the invention is inserted into an expressionvector, transformed or transfected into an appropriate host cell andcultivated under conditions suitable for expression.

One embodiment of the invention includes the use of gene transfer tocells, including microorganisms, for the production of proteins. Thegene for the protein of interest may be transferred into appropriatehost cells followed by culture of cells under the appropriateconditions. A nucleic acid encoding virtually any polypeptide may beemployed. The generation of recombinant expression vectors, and theelements included therein, are known to one skilled in the art and arebriefly discussed herein. Examples of mammalian host cell lines include,but are not limited to ero and HeLa cells, other B- and T-cell lines,such as CEM, 721.221, H9, Jurkat, Raji, as well as cell lines of Chinesehamster ovary (CHO), W138, BHK, COS-7, 293, HepG2, 3T3, RIN and MDCKcells. In addition, a host cell strain may be chosen that modulates theexpression of the inserted sequences, or that modifies and processes thegene product in the manner desired. Such modifications (e.g.,glycosylation) and processing (e.g., cleavage) of protein products maybe important for the function of the protein. Different host cells havecharacteristic and specific mechanisms for the post-translationalprocessing and modification of proteins. Appropriate cell lines or hostsystems can be chosen to ensure the correct modification and processingof the foreign protein expressed.

A number of selection systems may be used including, but not limited toHSV thymidine kinase, hypoxanthine-guanine phosphoribosyltransferase,and adenine phosphoribosyltransferase genes, in tk-, hgprt- oraprt-cells, respectively. Also, anti-metabolite resistance can be usedas the basis of selection: for dhfr, which confers resistance totrimethoprim and methotrexate; gpt, which confers resistance tomycophenolic acid; neo, which confers resistance to the aminoglycosideG418; and hygro, which confers resistance to hygromycin.

G. Nucleic Acids

The present invention may include recombinant polynucleotides encodingthe proteins, polypeptides, peptides of the invention, such as thoseencoding antigenic peptides.

In particular embodiments, the invention concerns isolated nucleic acidsegments and recombinant vectors incorporating nucleic acid sequencesthat encode an autoantigen and/or a MHC molecule. The term “recombinant”may be used in conjunction with a polypeptide or the name of a specificpolypeptide, and this generally refers to a polypeptide produced from anucleic acid molecule that has been manipulated in vitro or that is areplication product of such a molecule.

The nucleic acid segments used in the present invention, regardless ofthe length of the coding sequence itself, may be combined with othernucleic acid sequences, such as promoters, polyadenylation signals,additional restriction enzyme sites, multiple cloning sites, othercoding segments, and the like, such that their overall length may varyconsiderably. It is therefore contemplated that a nucleic acid fragmentof almost any length may be employed, with the total length preferablybeing limited by the ease of preparation and use in the intendedrecombinant nucleic acid protocol. In some cases, a nucleic acidsequence may encode a polypeptide sequence with additional heterologouscoding sequences, for example to allow for purification of thepolypeptide, transport, secretion, post-translational modification, orfor therapeutic benefits such as targeting or efficacy. A tag or otherheterologous polypeptide may be added to the modifiedpolypeptide-encoding sequence, wherein “heterologous” refers to apolypeptide that is not the same as the modified polypeptide.

V. PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATION

Provided herein are pharmaceutical compositions useful for the treatmentof disease.

A. Pharmaceutical Compositions

The antigen-MHC nanoparticle complexes can be administered alone or incombination with a carrier, such as a pharmaceutically acceptablecarrier in a composition. Compositions of the invention may beconventionally administered parenterally, by injection, for example,intravenously, subcutaneously, or intramuscularly. Additionalformulations which are suitable for other modes of administrationinclude oral formulations. Oral formulations include such normallyemployed excipients such as, for example, pharmaceutical grades ofmannitol, lactose, starch, magnesium stearate, sodium saccharine,cellulose, magnesium carbonate and the like. These compositions take theform of solutions, suspensions, tablets, pills, capsules, sustainedrelease formulations or powders and contain about 10% to about 95% ofactive ingredient, preferably about 25% to about 70%. The preparation ofan aqueous composition that contains an antigen-MHC-nanoparticle complexthat modifies the subject's immune condition will be known to those ofskill in the art in light of the present disclosure. In certainembodiments, a composition may be inhaled (e.g., U.S. Pat. No.6,651,655, which is specifically incorporated by reference in itsentirety). In one embodiment, the antigen-MHC-nanoparticle complex isadministered systemically.

Typically, compositions of the invention are administered in a mannercompatible with the dosage formulation, and in such amount as will betherapeutically effective and immune modifying. The quantity to beadministered depends on the subject to be treated. Precise amounts ofactive ingredient required to be administered depend on the judgment ofthe practitioner. However, suitable dosage ranges are of the order often to several hundred nanograms or micrograms antigen-MHC-nanoparticlecomplex per administration. Suitable regimes for initial administrationand boosters are also variable, but are typified by an initialadministration followed by subsequent administrations.

In many instances, it will be desirable to have multiple administrationsof a peptide-MHC-nanoparticle complex, about, at most about or at leastabout 3, 4, 5, 6, 7, 8, 9, 10 or more. The administrations will normallyrange from 2 day to twelve week intervals, more usually from one to twoweek intervals. Periodic boosters at intervals of 0.25-5 years, usuallytwo years, may be desirable to maintain the condition of the immunesystem. The course of the administrations may be followed by assays forinflammatory immune responses and/or autoregulatory T cell activity.

In some embodiments, pharmaceutical compositions are administered to asubject. Different aspects of the present invention involveadministering an effective amount of a antigen-MHC-nanoparticle complexcomposition to a subject. Additionally, such compositions can beadministered in combination with modifiers of the immune system. Suchcompositions will generally be dissolved or dispersed in apharmaceutically acceptable carrier or aqueous medium.

The phrases “pharmaceutically acceptable” or “pharmacologicallyacceptable” refer to molecular entities and compositions that do notproduce an adverse, allergic, or other untoward reaction whenadministered to an animal, or human. As used herein, “pharmaceuticallyacceptable carrier” includes any and all solvents, dispersion media,coatings, antibacterial and antifungal agents, isotonic and absorptiondelaying agents, and the like. The use of such media and agents forpharmaceutical active substances is well known in the art. Exceptinsofar as any conventional media or agent is incompatible with theactive ingredients, its use in immunogenic and therapeutic compositionsis contemplated.

The pharmaceutical forms suitable for injectable use include sterileaqueous solutions or dispersions; formulations including sesame oil,peanut oil, or aqueous propylene glycol; and sterile powders for theextemporaneous preparation of sterile injectable solutions ordispersions. In all cases the form must be sterile and must be fluid tothe extent that it may be easily injected. It also should be stableunder the conditions of manufacture and storage and must be preservedagainst the contaminating action of microorganisms, such as bacteria andfungi.

The compositions may be formulated into a neutral or salt form.Pharmaceutically acceptable salts, include the acid addition salts(formed with the free amino groups of the protein) and which are formedwith inorganic acids such as, for example, hydrochloric or phosphoricacids, or such organic acids as acetic, oxalic, tartaric, mandelic, andthe like. Salts formed with the free carboxyl groups can also be derivedfrom inorganic bases such as, for example, sodium, potassium, ammonium,calcium, or ferric hydroxides, and such organic bases as isopropylamine,trimethylamine, histidine, procaine and the like.

The carrier may be a solvent or dispersion medium containing, forexample, water, ethanol, polyol (for example, glycerol, propyleneglycol, and liquid poly(ethylene glycol), and the like, suitablemixtures thereof, and vegetable oils. The proper fluidity can bemaintained, for example, by the use of a coating, such as lecithin, bythe maintenance of the required particle size in the case of dispersion,and by the use of surfactants. The prevention of the action ofmicroorganisms can be brought about by various antibacterial andantifungal agents, for example, parabens, chlorobutanol, phenol, sorbicacid, thimerosal, and the like. In many cases, it will be preferable toinclude isotonic agents, for example, sugars or sodium chloride.Prolonged absorption of the injectable compositions can be brought aboutby the use in the compositions of agents delaying absorption, forexample, aluminum monostearate and gelatin.

Sterile injectable solutions are prepared by incorporating the activecompounds in the required amount in the appropriate solvent with variousof the other ingredients enumerated above, as required, followed bysterilization. Sterilization of the solution will be done in such a wayas to not diminish the therapeutic properties of theantigen-MHC-nanoparticle complex. Generally, dispersions are prepared byincorporating the various sterilized active ingredients into a sterilevehicle which contains the basic dispersion medium and the requiredother ingredients from those enumerated above. In the case of sterilepowders for the preparation of sterile injectable solutions, thepreferred methods of preparation are vacuum-drying and freeze-dryingtechniques, which yield a powder of the active ingredient, plus anyadditional desired ingredient from a previously sterilized solutionthereof. One such method of sterilization of the solution is sterilefiltration, however, this invention is meant to include any method ofsterilization that does not significantly decrease the therapeuticproperties of the antigen-MHC-nanoparticle complexes. Methods ofsterilization that involve intense heat and pressure, such asautoclaving, may compromise the tertiary structure of the complex, thussignificantly decreasing the therapeutic properties of theantigen-MHC-nanoparticle complexes.

An effective amount of therapeutic composition is determined based onthe intended goal. The term “unit dose” or “dosage” refers to physicallydiscrete units suitable for use in a subject, each unit containing apredetermined quantity of the composition calculated to produce thedesired responses discussed above in association with itsadministration, i.e., the appropriate route and regimen. The quantity tobe administered, both according to number of treatments and unit dose,depends on the result and/or protection desired. Precise amounts of thecomposition also depend on the judgment of the practitioner and arepeculiar to each individual. Factors affecting dose include physical andclinical state of the subject, route of administration, intended goal oftreatment (alleviation of symptoms versus cure), and potency, stability,and toxicity of the particular composition. Upon formulation, solutionswill be administered in a manner compatible with the dosage formulationand in such amount as is therapeutically or prophylactically effective.The formulations are easily administered in a variety of dosage forms,such as the type of injectable solutions described above.

B. Combination Therapy

The compositions and related methods of the present invention,particularly administration of an antigen-MHC-nanoparticle complex, mayalso be used in combination with the administration of traditionaltherapies. These include, but are not limited to, Avonex (interferonbeta-1a), Betaseron (interferon beta-1b), Copaxone (glatiramer acetate),Novantrone (mitoxantrone), Rebif (interferon beta-1a), Tysabri(natalizumab), Gilenya (fingolimod), Glatiramer, steroids, Cytoxan,Imuran, Baclofen, deep brain stimulation, Ampyra (dalfampridine),acupuncture, and physical therapy.

When combination therapy is employed, various combinations may beemployed, for example antigen-MHC-nanoparticle complex administration is“A” and the additional agent is “B”:

A/B/A B/A/B B/B/A A/A/B A/B/B B/A/A A/B/B/B B/A/B/B B/B/B/A B/B/A/BA/A/B/B A/B/A/B A/B/B/A/ B/B/A/A B/A/B/A B/A/A/B A/A/A/B B/A/A/A A/B/A/AA/A/B/A

Administration of the peptide-MHC complex compositions of the presentinvention to a patient/subject will follow general protocols for theadministration of such compounds, taking into account the toxicity, ifany. It is expected that the treatment cycles would be repeated asnecessary. It also is contemplated that various standard therapies, suchas hydration, may be applied in combination with the described therapy.

C. In Vitro or Ex Vivo Administration

As used herein, the term in vitro administration refers to manipulationsperformed on cells removed from or outside of a subject, including, butnot limited to cells in culture. The term ex vivo administration refersto cells which have been manipulated in vitro, and are subsequentlyadministered to a subject. The term in vivo administration includes allmanipulations performed within a subject, including administrations.

In certain aspects of the present invention, the compositions may beadministered either in vitro, ex vivo, or in vivo. In certain in vitroembodiments, autologous T cells are incubated with compositions of thisinvention. The cells or tissue can then be used for in vitro analysis,or alternatively for ex vivo administration.

VI. EXAMPLES

The following examples are given for the purpose of illustrating variousembodiments of the invention and are not meant to limit the presentinvention in any fashion. One skilled in the art will appreciate readilythat the present invention is well adapted to carry out the objects andobtain the ends and advantages mentioned, as well as those objects, endsand advantages inherent herein. The present examples, along with themethods described herein are presently representative of embodiments andare exemplary, and are not intended as limitations on the scope of theinvention. Changes therein and other uses which are encompassed withinthe spirit of the invention as defined by the scope of the claims willoccur to those skilled in the art.

Example 1. Preparation and Analysis of pMHC Nanoparticles

pMHC Production

Two different methods were used to express recombinant pMHC class Icomplexes. The first involved re-folding MHC class I heavy and lightchains expressed in bacteria in the presence of peptide, followed bypurification via gel filtration and anion exchange chromatography, asdescribed (Garboczi, D. N. et al. (1992) Proc Natl. Acad Sci USA89:3429-3433; Altman, J. D. et al. (1996) Science 274:94-96). The secondinvolved expressing MHC class I complexes at high yields inlentiviral-transduced freestyle CHO cells as single chain constructs inwhich the peptide-coding sequence, the MHC class I light and heavychains are sequentially tethered with flexible GS linkers (Yu, Y. Y. etal. (2002) J Immunol 168:3145-3149) followed by a carboxyterminal linkerencoding a BirA site, a 6×His tag (SEQ ID NO: 70) ending with a freeCys. The secreted proteins were purified from culture supernatants usingnickel columns and anion exchange chromatography and used directly forNP coating or biotinylated to produce pMHC tetramers usingfluorochrome-conjugated streptavidin. Tetramers generated usingrepresentative single-chain pMHC complexes encoding the IGRP₂₀₆₋₂₁₄autoantigenic peptide or its mimic NRP-V7 efficiently bind to cognatemonoclonal autoreactive CD8+ T-cells but not to their polyclonalcounterparts (not shown), as determined by flow cytometry.

Recombinant pMHC class II monomers were initially purified fromDrosophila SC2 cells transfected with constructs encoding I-Aβ and I-Aαchains carrying c-Jun or c-Fos leucine zippers, respectively, and a BirAand 6×His tags (SEQ ID NO: 70) as previously described (Stratmann, T. etal. (2000) J Immunol 165:3214-3225, Stratmann, T. et al. (2003) J. Clin.Invest. 112:3214-3225). As the yields of this approach were generallylow and time-consuming, Applicant developed an expression system infreestyle CHO cells transduced with lentiviruses encoding amonocistronic message in which the peptide-IAβ and IAα chains of thecomplex are separated by the ribosome skipping P2A sequence (Hoist, J.et al. (2006) Nat Protoc 1:406-417). As with the single chain pMHC classI constructs described above, a linker encoding a BirA site, a 6×His tag(SEQ ID NO: 70) and a free Cys was added to the carboxyterminal end ofthe construct. The self-assembled pMHC class II complexes were purifiedfrom the cell culture supernatants by nickel chromatography followed byanion exchange and used for coating onto NPs or processed forbiotinylation and tetramer formation as described above. pMHC class IItetramers generated using a representative pMHC class II complexencoding the 2.5 mi autoantigenic peptide are specifically andefficiently bound by cognate monoclonal autoreactive CD4+ T-cells, asdetermined by flow cytometry.

pMHC Tetramer Staining

PE-conjugated TUM-H-2K^(d), NRP-V7-H-2K^(d), IGRP₂₀₆₋₂₁₄-H-2K^(d),HEL₁₄₋₂₂/IA^(g7) and BDC2.5 mi/IA^(g7) tetramers were prepared usingbiotinylated pMHC monomers as described (Stratmann, T. et al. (2000) JImmunol 165:3214-3225; Stratmann, T. et al. (2003) J. Clin. Invest.112:3214-3225; Amrani, A. et al. (2000) Nature 406:739-742). Peripheralblood mononuclear cells, splenocytes and lymph node CD8+ or CD4+ T-cellswere stained with tetramer (5 ug/mL) in FACS buffer (0.1% sodium azideand 1% FBS in PBS) for 1 h at 4° C., washed, and incubated withFITC-conjugated anti-CD8a or anti-CD4 (5 μg/mL) and PerCP-conjugatedanti-B220 (2 μg/mL; as a ‘dumb’ gate) for 30 min at 4° C. Cells werewashed, fixed in 1% PFA/PBS and analyzed by FACS.

NP Synthesis

Gold nanoparticles (GNPs) were synthesized using chemical reduction ofgold chloride with sodium citrate as described (Perrault, S. D. et al.(2009) Nano Lett 9:1909-1915). Briefly, 2 mL of 1% of HAuCl₄ (SigmaAldrich) was added to 100 mL H₂O under vigorous stirring and thesolution heated in an oil bath. Six (for 14 nm GNPs) or two mL (for 40nm GNPs) of 1% Na Citrate were added to the boiling HAuCl₄ solution,which was stirred for an additional 10 min and then cooled down to roomtemperature. GNPs were stabilized by the addition of 1 uMol of thiol-PEGlinkers (Nanocs, Mass.) functionalized with —COOH or —NH₂ groups asacceptors of pMHC (Tables 1 and 2). Pegylated GNPs were washed withwater to remove free thiol-PEG, concentrated and stored in water forfurther analysis. NP density was via spectrophotometry and calculatedaccording to Beer's law.

The SFP series iron oxide NPs (SFP IONPs) were produced by thermaldecomposition of iron acetate in organic solvents in the presence ofsurfactants, then rendered solvent in aqueous buffers by pegylation(Xie, J. et al. (2007) Adv Mater 19:3163; Xie, J. et al. (2006) PureAppl. Chem. 78:1003-1014; Xu, C. et al. (2007) Polymer International56:821-826). Briefly, 2 mMol Fe(acac)₃ (Sigma Aldrich, Oakville, ON)were dissolved in a mixture of 10 mL benzyl ether and oleylamine andheated to 100° C. for 1 hr followed by 300° C. for 2 hr with refluxunder the protection of a nitrogen blanket. Synthesized NPs wereprecipitated by addition of ethanol and resuspended in hexane. Forpegylation of the IONPs, 100 mg of different 3.5 kDa DPA-PEG linkers(S1-S5 in Table 1; Jenkem Tech USA) were dissolved in a mixture of CHCl₃and HCON(CH₃)₂ (DMF). The NP solution (20 mg Fe) was then added to theDPA-PEG solution and stirred for 4 hr at room temperature. Pegylated SFPNPs were precipitated overnight by addition of hexane and thenresuspended in water. Trace amounts of aggregates were removed byhigh-speed centrifugation (20,000×g, 30 min), and the monodisperse SFPNPs were stored in water for further characterization and pMHCconjugation. The concentration of iron in IONP products was determinedby spectrophotometry at A410 in 2N HCL. Based on the molecular structureand diameter of SFP NPs (Fe₃O₄; 8±1 nm diameter) (Xie, J. et al. (2007)Adv Mater 19:3163; Xie, J. et al. (2006) Pure Appl. Chem. 78:1003-1014),Applicant estimates that SFP solutions containing 1 mg of iron contain5×10¹⁴ NPs.

Applicant subsequently developed a new IONP design that allowed theformation, also by thermal decomposition but in a single step, ofpegylated IONPs in the complete absence of surfactants (PF seriesIONPs). In this novel design, PEG molecules were used both as reducingreagents and as surfactants. In a typical reaction, 3 g PEG (2 kDa) weremelted slowly in a 50 mL round bottom boiling flask at 100° C. and thenmixed with 7 mL of benzyl ether and 2 mMol Fe(acac)₃. The reaction wasvigorously stirred for one hr and heated to 260° C. with reflux for anadditional two hr. The reaction mixture was cooled down to roomtemperature, transferred to a centrifugation tube and mixed with 30 mLwater. Insoluble materials were removed by centrifugation at 2,000×g for30 min. The free PEG molecules were removed by ultrafiltration throughAmicon-15 filters (MWCO 100 kDa, Millipore, Billerica, Mass.). Applicantwas able to generate IONPs with most, albeit not all of the PEGmolecules tested (Table 1, P1-P5). The size of the IONPs varieddepending on the functional groups of the PEG linkers used in thethermal decomposition reactions (Tables 1 and 2). The NPs could bereadily purified using magnetic (MACS) columns (Miltenyi Biotec, Auburn,Calif.) or an IMag cell separation system (BD BioSciences, Mississauga,ON). The purified IONPs were stored in water or in various buffers (pH5-10) at room temperature or at 4° C. without any detectableaggregation. NP density was calculated as described above for SFP NPs.

pMHC Conjugation of NPs

pMHC conjugation to NPs produced with PEG linkers carrying distal—NH₂ or—COOH groups was achieved via the formation of amide bonds in thepresence of 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride(EDC). NPs (GNP—C, SFP—C and PF-C, Table 2) with —COOH groups were firstdissolved in 20 mM MES buffer, pH 5.5. N-hydroxysulfosuccinimide sodiumsalt (sulpha-NHS, Thermo scientific, Waltham, Mass., final concentration10 mM) and EDC (Thermo scientific, Waltham, Mass., final concentration 1mM) were added to the NP solution. After 20 min of stirring at roomtemperature, the NP solution was added drop-wise to the solutioncontaining pMHC monomers dissolved in 20 mM borate buffer (pH 8.2). Themixture was stirred for additional 4 hr. To conjugate pMHCs toNH₂-functionalized NPs (GNP-N, SFP-N and PF-N, Table 2), pMHC complexeswere first dissolved in 20 mM MES buffer, pH 5.5, containing 100 mMNaCl. Sulpha-NHS (10 mM) and EDC (5 mM) were then added to the pMHCsolution. The activated pMHC molecules were then added to the NPsolution in 20 mM borate buffer (pH 8.2), and stirred for 4 hr at roomtemperature.

To conjugate pMHC to maleimide-functionalized NPs (SFP-M and PF-M, Table2 and FIG. 1C), pMHC molecules were first incubated withTributylphospine (TBP, 1 mM) for 4 hr at room temperature. pMHCsengineered to encode a free carboxyterminal Cys residue were then mixedwith NPs in 40 mM phosphate buffer, pH 6.0, containing 2 mM EDTA, 150 mMNaCl, and incubated overnight at room temperature. pMHCs were covalentlybound with NPs via the formation of a carbon-sulfide bond betweenmeleimide groups and the Cys residue.

Click chemistry was used to conjugate pMHC or avidin to NPsfunctionalized with azide groups (SFP-Z, Table 2). For this reaction,pMHC or avidin molecules were first incubated with dibenzocyclooctyl(DBCO, Click Chemistry Tools, Scottdale, Ariz.) reagent for 2 hr at roomtemperature. Free DBCO molecules were removed by dialysis overnight.pMHC- or avidin-DBCO conjugates were then incubated with SFP-Z for 2 hr,resulting in formation of triazole bonds between pMHCs or avidinmolecules and NPs.

Unconjugated pMHC complexes in the different pMHC-NP conjugatingreactions were removed by extensive dialysis against PBS, pH 7.4, at 4°C. though 300 kDa molecular weight cut off membranes (Spectrum labs).Alternatively, pMHC-conjugated IONPs were purified by magneticseparation. The conjugated NPs were concentrated by ultrafiltrationthrough Amicon Ultra-15 units (100 kDa MWCO) and stored in PBS.

Electron Microscopy, Dynamic Light Scattering, DLS and Small AngleElectro Beam Diffraction

The core size and dispersity of unconjugated and pMHC-conjugated NPswere first assessed via transmission electron microscopy (TEM, HitachiH7650). Dynamic light scattering (DLS) was used to determine thepMHC-NPs' hydrodynamic size, zeta potential and monodisperity using aZetaSizer instrument (Malvern, UK). The chemical nature of the ironoxide core of the PF series of NPs was evaluated using small angleelectro beam diffraction (SEBD).

Fourier Transformation Infrared Spectroscopy

The surface chemical properties of the PF-series IONP designs wereevaluated using Fourier Transformation Infrared spectroscopy (FTIR). TheFTIR spectra of control PEG and PEG anchored on the PF-NP surface wereobtained using a Nicolet FTIR spectrophotometer on an ATR (attenuatedtotal reflection) mode. Each of the spectra was recorded as the averageof 256 scans at 4 cm⁻¹ spectral resolution. The stretching vibrationsignatures of the PEG backbone C—O—C groups and their distalpMHC-acceptor functional groups were identified.

Agarose Gel Electrophoresis

To quickly evaluate changes on the NP charge as a function of pegylationor pMHC coating, NPs were subjected to electrophoresis on 0.8% agarosegels. Pegylated NPs migrated to negative or positive poles depending onthe overall surface charge. Coomassie blue staining was done to confirmco-migration of the pMHCs with the NPs.

Native and Denaturing Polyacrylamide Gel Electrophoresis

pMHC conjugated NPs were subjected to native-PAGE (10%) and SDS-PAGE(12%) analyses to confirm absence of free (unconjugated pMHC) in thepMHC-NP preparations and to confirm presence of intact trimolecular pMHCcomplexes on the NP's surface.

pMHC Valency Measurements

To evaluate the number of pMHC monomers conjugated onto individual NPs(pMHC valency), we measured the pMHC concentration of the pMHC-NP prepsusing different approaches, including Bradford assay (ThermoScientific), amino acid analysis (HPLC-based quantification of 17different amino acids in hydrolyzed pMHC-NP preparations) (University ofToronto), dot-ELISA and signature peptide analysis by mass spectrometry)and the values converted to ratios of pMHC molecular number to NPnumber. Briefly, in the “dot-ELISA” approach, pMHC-conjugated andunconjugated NPs and pMHC monomer solutions (as standards) were seriallydiluted in PBS and then absorbed to a PVDF membrane in a multiwellfilter plate (PALL Corporation). The plate was allowed to partially dryat room temperature and then incubated with pMHC specific primaryantibodies (i.e., anti-β2M and anti-K^(d) antibodies for pMHC classI-coated NPs, clones 2M2 and SF1-1.1, BioLegend, San Diego, Calif.),followed by HRP- or AP-conjugated secondary antibodies. Upon developmentof the enzymatic color reactions, the contents of the wells weretransferred to wells in a conventional ELISA plate and their absorbancesmeasured at 450 nm using a plate reader. For the signature peptide massspectrometry approach, pMHC-specific trypsin peptides (signaturepeptides TWTAADTAALITR (SEQ ID NO: 71) for K^(d) complexes andAQNSELASTANMLR (SEQ ID NO: 72) for I-A^(g7) complexes) were identifiedvia mass spectrometry. The corresponding synthetic peptides were labeledwith stable isotopes (AQUA peptide synthesis, Sigma Aldrich). Theisotope-labeled peptides were then serially diluted to definedconcentrations and mixed with pMHC-conjugated NPs for trypsin digestion.The mixtures were subjected to mass spectroscopy (Agilent QT0F6520) toquantify the ratios of isotope-labeled versus unlabeled signaturepeptides, as a read-out of pMHC concentration. Since the valuesgenerated by these different methods were similar, the Bradford assay(using unconjugated NPs as blanks) became the method of choice for easeand simplicity.

Agonistic Activity of pMHC-NPs In Vitro

FACS-sorted splenic CD8+ cells from TCR-TG mice (2.5×10⁵ cells/mL) wereincubated with serially diluted pMHC conjugated or control NPs for 24-48h at 37° C. The supernatants were assayed for IFNγ by ELISA. Thecultured cells were pulsed with 1 mCi of [³H]-thymidine and harvestedafter 24 h to measure [³H] incorporation.

pMHC-NP Therapy

Cohorts of 10 wk-old female NOD mice were injected i.v. with pMHC-coatedNPs in PBS twice a week for 5 wk (10 doses in total). Increases in thesize of tetramer+CD8+ or CD4+ T-cell pools in blood, spleen, lymph nodesand/or marrow, as well as their phenotypic properties, were assessed byflow cytometry as described (Tsai, S. et al. (2010) Immunity 32:568-580)(and Clemente-Casares et al., submitted). In other experiments, micedisplaying blood glucose levels >11 mM for 2 days were treated i.v.twice a wk with pMHC-NP and monitored for hyperglycemia until stablynormoglycemic (for 4 wk). Animals were also assessed daily forglycosuria and given human insulin isophane (1 IU per day) s.c. if 3+.

Statistical Analyses

Data were compared by two-tailed Student's t, Mann-Whitney U,Chi-Square, or two-way ANOVA tests. Statistical significance was assumedat P<0.05.

Mice

NOD/Lt mice were from the Jackson Lab (Bar Harbor, Me.). 17.4a/8.3(8.3-NOD), 17.6a/8.3a (17.6-NOD) and BDC2-5-NOD mice have been described(Katz, J. D. et al. (1993) Cell 74:1089-1100; Verdaguer, J. et al.(1997) J Exp Med 186:1663-1676; Han, B. et al. (2005) J Clin Invest115:1879-1887).

Example 2. Production of T1D-Relevant pMHC Class II

Several different T1D-relevant and irrelevant (i.e., negative control)peptide/I-A^(g7) complexes were produced in eukaryotic (S2 or CHOcells). Studies using tetramers generated from these monomer prepsconfirm that these monomers are secreted into the supernatant asproperly folded pMHC complexes. FIG. 2 provides an example.

Reversal of hyperglycemia in NOD mice by treatment with T1D-relevantpMHC class II-NPs

Diabetic NOD mice were treated twice a wk with 7.5 μg of pMHC classII-coated-NPs. Mice were considered cured when normoglycemic for 4 wk,at which point treatment was withdrawn. As shown in FIG. 3 , whereas 2.5mi/I-A^(g7)-, IGRP₁₂₈₋₁₄₅/I-A^(g7)-, and IGRP₄₋₂₂/I-A^(g7)-NPs reversedhyperglycemia in 90-100% of mice (n=29 mice), treatment withHEL₁₄₋₂₂/I-A^(g7)-NPs (a foreign pMHC) had no effect. Intraperitonealglucose tolerance tests (IPGTTs) in cured mice >30 wk after treatmentwithdrawal yielded curves that were very similar to those in age-matchednon-diabetic untreated controls and significantly different than thoseobtained in untreated acutely diabetic NOD mice (FIG. 4 ). Thus, NPscoated with T1D-relevant pMHC class II restore glucose homeostasis indiabetic mice.

T1D-Relevant pMHC Class II-NPs Expand Cognate Memory TR1 AutoregulatoryCD4+ T Cells

Studies of blood, spleens, pancreatic lymph nodes (PLNs), mesentericlymph nodes (MLNs) and bone marrow of 50 wk-old diabetic mice that hadbeen rendered normoglycemic by treatment with 2.5 mi/I-A^(g7)-NPsrevealed significantly increased percentages of 2.5 mi/I-A^(g7)tetramer+ CD4+ cells, as compared to mice studied at diabetes onset orage-matched non-diabetic untreated animals (FIG. 5 ). CD4+ T-cellexpansion was antigen-specific (FIG. 5 ). The tempo, magnitude anddistribution of expansion were similar for the three T1D-relevant pMHCclass II-NPs tested (FIG. 6 ). Phenotypic analyses of the NP-expandedtetramer+ cells vs. tetramer− cells in all these cohorts revealed amemory-like TR1 phenotype (FIG. 7 , top) with co-expression of theTR1-specific markers described recently (Gagliani, N. et al. (2013)Nature Medicine 19:739-746) (FIG. 7 , bottom):CD62^(low)/CD44^(high)/ICOS⁺/CD25⁻/FoxP3⁻/surface TGFβ⁺/CD49b⁺/LAG3⁺.That these cells were not FoxP3+ was confirmed in NOD mice expressingFoxP3 promoter-eGFP, in which all pMHC-NP-expanded cells wereeGFP-negative (not shown).

Consistent with these phenotypic data, tetramer+CD4+ cells sorted frompMHC-NP-treated mice responded to DCs pulsed with cognate peptide byalmost exclusively secreting IL-10 and, to a lower extent, IFNγ (FIG. 8and not shown). Importantly, purified CD4+ but not CD8+ T cells frompMHC-NP-treated donors inhibited T1D in NOD.scid mice transferred withdiabetogenic splenocytes and hosts treated with pMHC class II-NPs were100% protected for >100 days (not shown).

These pMHC class II-NP-expanded tetramer+ cells, unlike their tetramer−counterparts, inhibited the proliferation of non-cognate T-cells topeptide-pulsed DCs (presenting the peptides targeted by both theresponder and tetramer+TR1 cells). Addition of an anti-IL10 or anti-TGFβmAbs to the cultures partially inhibited the suppression, versuscultures receiving anti-IFNγ or rat-IgG (not shown). Most importantly,studies of diabetic mice treated with IGRP₄₋₂₂ or 2.5 mi/I-A^(g7)-NPsand blocking anti-IL-10, anti-TGFβ or anti-IFNγ mAbs or rat-IgG (FIG. 9) indicate that restoration of normoglycemia by pMHC class II-NPsrequires IL-10 and TGFβ but not IFNγ. However, studies in spontaneouslydiabetic NOD.Il10^(−/−) and NOD.Ifng^(−/−) mice suggest that expressionof both IL-10 and IFNγ are necessary for development of the TR1 cellsthat expand in response to pMHC class II-NPs; in these mice, pMHC-NPtherapy expanded Th2-like cells (NOD.Ifng^(−/−)) or IFNγ+/IL-4⁺/IL10⁻cells (NOD.Il10^(−/−) mice). Studies in diabetic IGRP^(−/−) NOD mice(unable to prime IGRP-reactive T cells) showed that these mice did notrespond to IGRP₄₋₂₂/I-A^(g7)-NPs (there was no T cell expansion orrestoration of normoglycemia) because these mice lacked IGRP₄₋₂₂-primedcells. In contrast, all the diabetic IGRP^(−/−) NOD mice treated with2.5 mi/I-A^(g7)-NPs cured (not shown). Thus, pMHC class II-NPs, likepMHC class I-NPs, operate by expanding disease-primed regulatory memory,but cannot prime these responses de novo because they lackco-stimulatory signals.

Lastly, studies with vaccinia virus (rVV) showed that pMHC classII-NP-treated NOD mice can readily clear an acute viral infection (FIG.10A). In agreement with this, treated mice can mount antibody responsesagainst a model antigen in adjuvant (FIG. 10B).

Example 3. Monospecific pMHC Class II-NPs Decrease the Severity of EAE

Applicant then tested the therapeutic potential of a pMHC class II-basednanomedicine in Experimental Autoimmune Encephalomye-litis (EAE). Thismodel was utilized in the most stringent test possible: to investigateif pMHC-NPs can reverse established EAE as opposed to prevent or bluntits development. This is not a trivial issue. A recent review ofinterventions in EAE shows that <1% of over 400 studies initiatedtreatment 21 days after EAE induction (Hoist, J. et al. (2006) NatProtoc 1:406-417); the reported data were obtained in mice in whichtreatment was initiated 21 days after EAE induction and improved diseasescores in a dose-dependent manner (FIG. 11 ).

Example 4. Synthesis and Quality Control of pMHC Class II-Coated NPs

Applicant developed an optimized iron oxide NP design that does notemploy surfactants for synthesis and yields highly stable, monodispersedpreparations that can be loaded with optimal pMHC loads. Althoughseveral different pMHC-coating chemistries can be used (FIG. 12A),Applicant regularly uses NPs functionalized with maleimide-conjugatedPEGs, which accept high valencies of pMHCs engineered to encode a freeCys at their carboxyterminal end (up to more than 60 pMHCs/NP). ThesepMHC class II-NPs are processed through several quality control checksto define pMHC valencies per NP (dot-ELISA, amino acid analysis), NPdensity, NP charge and NP size (metal core, as defined by TEM; andhydrodynamic diameter, as defined via dynamic light scattering (DLS)).FIG. 12B shows a representative TEM image and FIG. 12C shows DLSprofiles of pMHC-uncoated vs. coated NPs. A typical dosing regimeninvolves the administration of 1-50 μg of total pMHC (NP-coated) perdose (about 2 uL of the preparation diluted in 100 uL of PBS).

Example 5. Treatment with pMHC Class II-Coated NPs

The above data are consistent with data Applicant previously obtained inmice treated with pMHC class I-NPs: pMHC class II-NPs expand cognatememory regulatory T cells (in this case TR1) that suppress thepresentation of other autoantigenic peptides by local autoantigen-loadedAPCs (Amrani, A. et al. (2000) Nature 406:739-742).

Human TR1 CD4+ T-cell clones have been reported to kill certain subsetsof professional APCs, such as dendritic cells (DCs) (Amrani, A. et al.(2000) Nature 406:739-742). Applicant therefore investigated whether theantigen-specific TR1 cells that expand in response top MHC class II-NPtherapy suppressed autoimmunity by killing autoantigen-loaded APCs. Thiswas done by tranfusing 1:1 mixtures of DCs pulsed with 2.5 mi or GPIpeptides and labeled with PKH26 (2.5 mi-pulsed DCs) or CFSE (GPI-pulsedDCs), into NOD mice that had received 10 doses of 2.5 mi/IA^(g7)-NPsduring the preceding 5 weeks, or NOD mice that had not received anytreatment. The hosts were sacrificed 7 days later to compare the ratiosof PKH26+vs CFSE+ cells in the two different hosts. As shown in FIG. 13A(top panels), no differences were observed, suggesting that the TR1 CD4+T-cells that expanded in response to pMHC-NP therapy do not killantigen-expressing DCs.

To investigate whether this was a peculiarity of the type of APC used (aDC) or a general feature of other APC types, the above experiments wererepeated but using splenic B-cells as opposed to DCs. Unexpectedly, itwas found that the numbers of 2.5 mi-pulsed B-cells expanded (ratherthan decreased) in hosts that had been treated with 2.5mi/IA^(g7)-NPs-coated NPs (FIG. 13A, bottom panels). This was unexpectedbecause, based on the state-of-the-art, it was expected just theopposite outcome (a selective and specific decrease of 2.5 mi-pulsedB-cells as compared to their GPI-pulsed counterparts).

Applicant then ascertained whether such a B-cell-expanding effect ofpMHC class II-NP treatment could be documented by comparing the absolutenumbers and percentages of B-cells in the pancreas-draining (PLN) andnon-draining (MLN) lymph nodes of mice treated with 2.5 mi/IA^(g7)-NPsversus untreated controls. As shown in FIG. 13B, pMHC classII-NP-treated NOD mice had a marked increase in the percentage ofB-cells in the PLN but not MLN. No such differences were seen in the PLNvs MLN of untreated NOD mice, indicating that these effects were aconsequence of pMHC-NP therapy. Notably, there was a statisticallysignificant correlation between the frequency of 2.5 mi-specific TR1CD4+ T-cells in the PLNs of individual mice and the frequency ofPLN-associated B-cells, suggesting that such an increased recruitment ofB-cells to the PLNs of the pMHC-NP-treated NOD mice was driven by the2.5 mi-specific TR1 CD4+ T-cells that expanded in response to MHC-NPtherapy.

Collectively, these data raised the possibility that the B-cells thatexpanded in response to MHC-NP therapy might be B-regulatory cells, thatis B-cells that acquire the capacity to produce IL-10 in response tocognate interactions with the pMHC-NP-expanded TR1 CD4+ T-cells. Thiscase scenario posits that 2.5 mi-specific TR1 CD4+ T-cells would inducethe differentiation and expansion of undifferentiated chromograninA-specific B-cells (chromogranin A is the natural antigenic source ofthe 2.5 mi epitope) that have captured chromogranin A and thereforepresent the corresponding 2.5 mi/IA^(g7) pMHC complexes on theirsurface, to IL-10-producing Breg cells.

To test this hypothesis, Applicant transfused 2.5 mi- or GPI-pulsedB-cells (labeled with PKH26) from a strain of NOD mice in which one ofits two IL10 loci carries a targeted insertion of an IRES-eGFP cassettebetween the stop codon and polyadenylation signal of exon 5 (11), into2.5 mi/IA^(g7)-NP-treated or untreated NOD hosts.

Seven days after transfer, the flow cytometric phenotype of the donorPKH26+ B-cells in the hosts (FIG. 13C, top panel) was determined. Asshown in FIG. 13C (middle and bottom panels), a significant fraction ofthe donor B-cells expressed IL10-encoded eGFP and were both CD5+ andCD1dhigh. These are three key markers of Breg cells (Xie, J. et al.(2007) Adv Mater 19:3163; Xie, J. et al. (2006) Pure Appl. Chem.78:1003-1014). This was only seen with B-cells pulsed with 2.5 mi, butnot with B-cells pulsed with a negative control peptide (GPI), and itonly occurred in pMHC-NP-treated mice. Importantly, this effect wasmediated, at least in part, by the IL-10 pMHC-NP-expanded TR1 CD4+T-cells, because no such response was observed in IL-10-deficient NODhosts.

Taken together, these data demonstrate that pMHC class II-NP therapyinduces the differentiation and expansion of antigen-specific B-cellsinto B-regulatory cells.

The description of data suggesting the existence of B lymphocytes withregulatory properties can be found in literature dating back to 1974.Similarly to the TR1 CD4+ T-cells that expand in response to pMHC classII-NP therapy, Breg cells express immunosuppressive cytokines, includingIL-10 and TGFb, as well as other molecules that can inhibit pathogenicautoreactive T- and B-cells in an antigen-dependent and highly specificmanner, via cognate, pMHC class II-driven cell-to-cell interactions (Xu,C. et al. (2007) Polymer International 56:821-826). Although differentstimuli have been shown to be able to induce Breg formation in vitro,and to a much lesser extent in vivo, to the best of Applicant'sknowledge there is currently no therapeutic approach capable of inducingand expanding antigen-specific Breg cells in vivo. By eliciting highlydisease-specific TR1 CD4+ T-cells, Applicant demonstrates that pMHCclass II-based nanomedicines also elicit disease-specific Breg cells.Since Breg cells can also promote the differentiation of effector intoTR1 CD4+ T-cells, pMHC class II-based nanomedicines unleash a profoundand sustained immunosuppressive response that is highly antigen-specificand therefore capable of selectively suppressing autoimmune responseswithout compromising systemic immunity.

Example 6. Synthesis of Surface Functionalized Iron Oxide Nanoparticleby Thermal Decomposition of Iron Acetylacetonate, and BioconjugationThereof

PEG is melted. Benzyl ether and iron acetyle acetonate is added. After 1hr of heating at 105° C., the temperature is increased to 260° C. andrefluxed. After about 2 hr, iron nanoparticles form and the color of thesolution turns black. The reaction is cooled down to room temperatureand some water added to extract nanoparticles from the reaction vessel.The nanoparticles are purified by Miltenyi Biotec LS magnet column. Themaking of iron oxide nanoparticle protein conjugates include addingprotein and the iron nanoparticle at a buffered pH of 6.2-6.5 (0.15MNaCl and 2 mM EDTA), stirring at room temperature for 12-14 hours, andpurifying protein conjugated particle by Miltenyi Biotec LS magnetcolumn.

It should be understood that although the present invention has beenspecifically disclosed by preferred embodiments and optional features,modification, improvement and variation of the inventions embodiedtherein herein disclosed may be resorted to by those skilled in the art,and that such modifications, improvements and variations are consideredto be within the scope of this invention. The materials, methods, andexamples provided here are representative of preferred embodiments, areexemplary, and are not intended as limitations on the scope of theinvention.

The invention has been described broadly and generically herein. Each ofthe narrower species and subgeneric groupings falling within the genericdisclosure also form part of the invention. This includes the genericdescription of the invention with a proviso or negative limitationremoving any subject matter from the genus, regardless of whether or notthe excised material is specifically recited herein.

In addition, where features or aspects of the invention are described interms of Markush groups, those skilled in the art will recognize thatthe invention is also thereby described in terms of any individualmember or subgroup of members of the Markush group.

The use of the term “or” in the claims is used to mean “and/or” unlessexplicitly indicated to refer to alternatives only or the alternativesare mutually exclusive, although the disclosure supports a definitionthat refers to only alternatives and “and/or.”

As used in this specification and claim(s), the words “comprising” (andany form of comprising, such as “comprise” and “comprises”), “having”(and any form of having, such as “have” and “has”), “including” (and anyform of including, such as “includes” and “include”) or “containing”(and any form of containing, such as “contains” and “contain”) areinclusive or open-ended and do not exclude additional, unrecitedelements or method steps.

Throughout this disclosure, various publications, patents and publishedpatent specifications are referenced by an identifying citation. Allpublications, patent applications, patents, and other referencesmentioned herein are expressly incorporated by reference in theirentirety, to the same extent as if each were incorporated by referenceindividually. In case of conflict, the present specification, includingdefinitions, will control.

TABLE 1 Functionalized PEG linkers Linker Types PEG Code of NanoparticleLinkers M.W. (kDa) Functional group Structure A1 Gold nanoparticle(GNP-C) Thio-PEG- carboxyl 3.5 Amine (—NH₂)

A2 Gold nanoparticle (GNP-N) Thio-PEG- amine 3.5 Carboxyl (—COOH)

S1 Iron oxide Nanoparticle (SFP-C) Dopamine- PEG-carboxyl 3.5 Carboxyl(—COOH)

S2 Iron oxide Nanoparticle (SFP-N) Dopamine- PEG-amine 3.5 Amine (—NH₂)

S3 Iron oxide Nanoparticle (SFP-Z) Dopamine- PEG-azide 3.5 Azide (—N₃)

S4 Iron oxide Nanoparticle (SFP-M) Dopamine- PEG-maleimide 3.5

S5 Iron oxide Nanoparticle (SFP-O) Dopamine- PEG- Orthopyridyl disulfide3.5

P1 Iron oxide Nanoparticle (PF-C) carboxyl- PEG-carboxyl 2.0 Carboxyl(—COOH)

P2 Iron oxide Nanoparticle (PF-N) Methoxy- PEG-amine 2.0 Amine (—NH₂)

P3 Iron oxide Nanoparticle (PF-M) Methoxy- PEG- maleimide 2.0

P4 Iron oxide Nanoparticle (PF-O) Methoxy- PEG- Orthopyridyl disulfide2.0

P5 Iron oxide Nanoparticle (PF) PEG 2.0 Hydroxyl (—OH)

TABLE 2 Nanoparticle designs and pMHC-binding capacity. NanoparticleSynthesis pMHC conjugation Precipit- pMHC- ation/ binding Magnetic SizeLinker Aggre- capacity Orient- purifi- Type (nm) (Code) gation Bond(pMHCs/NP) ation cation Gold 14 ± 2  A1 No Amide 200 Random No GNP-CGold 14 ± 2  A2 No Amide 263 Random No GNP-N Gold 40 ± 6  A1 No Amide5.250 Random No GNP-C Iron 7.4 ± 1.2 S1 No Amide 54 Random No OxideSFP-C Iron 7.4 ± 1.2 S2 Yes Amide 31 Random No Oxide SFP-N Iron 7.4 ±1.2 S3 No Triazole 50 Random Slow Oxide SFP-Z Iron 7.4 ± 1.2 S4 YesCarbon- <10 Directional No Oxide Sulfide SFP-M Iron 7.4 ± 1.2 S5 NoDisulfide <5 Directional No Oxide SFP-O Iron 14.6 ± 3.8  P1 No Amide 56Random No Oxide PF-C Iron 20.4 ± 4.2  P2 Yes Amide 210 Random No OxidePF-N Iron 23.5 ± 4.9  P3 No Carbon- 64 Directional Efficient OxideSulfide PF-M Iron Not P4 NA Disulfide NA Directional NA Oxide formedPF-O Iron 10.8 ± 2.7  P5 No None 0 NA No Oxide PF

What is claimed:
 1. A complex comprising a nanoparticle anddisease-relevant antigen-MHCII complexes for use in expanding and/ordeveloping populations of Tr1 cells and/or B-regulatory cells insubject, wherein the nanoparticle has a diameter selected from the groupof: from about 1 nm to about 100 nm in diameter; from about 1 nm toabout 50 nm in diameter or from about 1 nm to about 20 nm or from about5 nm to about 100 nm in diameter and wherein the ratio of the number ofantigen-MHCII complexes to nanoparticle is from about 10:1 to about1000:1.
 2. The complex of claim 1, wherein the complex has anantigen-MHCII density from about 0.05 pMHC/100 nm² of the surface areaof the nanoparticle to about 25 pMHC/100 nm² of the surface area of thenanoparticle.
 3. The complex of claim 1 or 2, wherein the antigen isderived from an autoantigen involved in an autoimmune response or mimicthereof, and optionally wherein the autoantigen is an epitope from anantigen expressed by pancreatic beta cells, IGRP, Insulin, GAD, IA-2 ormyelin oligodendrocyte protein (MOG).
 4. The complex claim 1, whereinthe nanoparticle is non-liposomal and/or has a solid core, preferably agold or iron oxide core.
 5. The complex of claim 1, wherein theantigen-MHCII is covalently or non-covalently linked to thenanoparticle.
 6. The complex of claim 1, wherein the antigen-MHCII iscovalently linked to the nanoparticle through a linker less than 5 kD insize.
 7. The complex of claim 1, wherein the nanoparticle isbioabsorbable and/or biodegradable.
 8. The complex of claim 1, whereinthe nanoparticle complex comprises antigen-MHCII complexes tonanoparticle ratio of from about 10:1 to about 100:1.
 9. The complex ofclaim 5, wherein the linker comprises polyethylene glycol.
 10. Thecomplex of claim 1, wherein the antigen-MHCII complexes are identical ordifferent.
 11. The complex of claim 9 or 10, wherein the linkers areidentical or different.
 12. A composition comprising a therapeuticallyeffect amount of the complex of claim 1 and a carrier.
 13. Thecomposition of claim 12, wherein the carrier is a pharmaceuticallyacceptable carrier.
 14. A method for making, preparing or obtaining thecomplex of claim 1, comprising coating or complexing antigen-MHCIIcomplexes onto a nanoparticle.
 15. A method for promoting the formation,expansion and recruitment of Tr1 cells and/or B-regulatory cells in anantigen-specific manner in a subject in need thereof, comprisingadministering to the subject an effective amount of the complex ofclaim
 1. 16. A method for treating or preventing a viral infection or anautoimmune disorder in a subject in need thereof comprisingadministering to the subject an effective amount of the complex of claim1, with the proviso that the antigen is a autoimmune-relevantautoantigen.
 17. The method of any one of claims 14-16, wherein thesubject is a mammal.
 18. The method of claim 15, wherein the autoimmunedisorder is selected from the group of diabetes, pre-diabetes, multiplesclerosis or a multiple sclerosis-related disorder, with the provisothat the antigen is relevant to the autoimmune disorder being treated.19. A kit comprising the complex of claim 1, and instructions for use.20. A method for making functionalized PEG iron oxide nanoparticlescomprising thermally decomposing iron acetyl acetonate in the presenceof functionalized PEG molecules and benzyl ether, wherein the thermaldecomposition occurs at a temperature from about 80 to about 300° C. 21.The method of claim 20, wherein the iron oxide nanoparticle iswater-soluble.
 22. The method of claim 20, wherein the thermaldecomposition comprises a single-step reaction.
 23. The method of claim20, wherein the thermal decomposition occurs in the presence offunctionalized PEG molecules.
 24. The method of claim 23, wherein thethermal decomposition is carried out in the presence of benzyl ether.25. The method of claim 20, wherein the temperature for the thermaldecomposition is about 80 to about 200° C., or about 80 to about 150°C., or about 100 to about 250° C., or about 100 to about 200° C., orabout 150 to about 250° C., or about 150 to about 250° C.
 26. The methodof claim 20, wherein the thermal decomposition is carried out for about1 to about 2 hours.
 27. The method of claim 20, wherein thenanoparticles are stable at about 4° C. in PBS without any detectabledegradation or aggregation.
 28. The method of claim 27, wherein thenanoparticles are stable for at least 6 months.
 29. The method of claim20, wherein the method further comprises purifying the nanoparticleswith a magnetic column.
 30. A method for making nanoparticle complexescomprising contacting pMHC with iron oxide nanoparticles as obtainedfrom claim 20, thereby providing nanoparticle complexes.
 31. The methodof claim 30, further comprising purifying the nanoparticles with amagnetic column.
 32. The method of claim 20, wherein the functionalizedPEG molecules are maleimide functionalized.
 33. The method of claim 20,wherein the functionalized PEG molecules are less than about 5kilodaltons.
 34. The method of claim 32, wherein the maleimidefunctionalized PEG molecules are methoxy-PEG molecules.